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Abstract
As many as 87% of children discontinue ADHD medication, which can lead to clinically
significant academic, cognitive, and social impairment. ADHD costs billions of dollars
to the healthcare and educational systems, and previous attempts to stem these costs and
increase ADHD medication adherence have been unsuccessful. The purpose of this study
was to determine if patient-centered medical homes (PCMH), which have been shown to
improve patient health outcomes, impact parental beliefs (benefits vs. risks) about ADHD
medication and adherence to ADHD medication. The theory of planned behavior was the
theoretical framework for this study. There were 294 parents of children between the
ages of 5 and 12 who had been prescribed ADHD medication who participated in a
quantitative self-administered survey. Parental beliefs were assessed using the Beliefs
About Medicines Questionnaire–Specific, and medication adherence was assessed using
the Morisky Medication Adherence Scale–8. The 2007 National Survey of Children’s
Health was used to determine group assignment. A MANCOVA was used to analyze the
data and found parents in the PCMH group scored significantly higher in their beliefs that
the benefits outweighed the risks of ADHD medication. However, no significant
differences were found between groups related to parental adherence to ADHD
medication. More research is recommended to learn how PCMHs can change positive
ADHD medication beliefs into better ADHD medication adherence. This study has social
change implications as it increases what is known about PCMHs and how they impact
health outcomes. It also supports previous literature in the need to deliver all PCMH
services, which is required to realize the full benefit of PCMHs.
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Chapter 1: Introduction to the Study
In this study I evaluated the impact of patient-centered medical homes (PCMHs)
on parental beliefs about attention-deficit hyperactivity disorder (ADHD) medication and
ADHD medication adherence. Adherence to medication is a critical element related to
pharmacological effectiveness, and it is especially important for people with chronic
conditions (Brown & Bussell, 2011). Recent literature showed as many as 21% of
children with ADHD stopped taking their medication during the first year, and of those
children who discontinued, 75% stopped taking their medication within the first 3 months
of initiating pharmacotherapy (Toomey, Sox, Rusinak, & Finkelstein, 2012). The
consequences of nonadherence to medication were an increased likelihood of social and
academic impairment, substance use, unsafe driving, and decreased quality of life. Adler
and Nierenberg (2015) reported up to 64% of individuals are nonadherent to their ADHD
medication and indicated nonadherence occured more frequently with the use of
immediate release stimulant medications. However, Ahmed and Aslani (2013) reported
nonadherence to ADHD medication is as high as 87%. ADHD can lead to significant
academic and social impairment, risky behaviors, and diminished quality of life.
The PCMHs have been reported to improve health outcomes (Homer et al., 2008,
Patient-Centered Primary Care Collaborative, 2015) and may decrease ADHD
medication nonadherence among children. Although there is a plethora of literature
available on PCMHs and treatment outcomes (An, 2016; Brown & Bussell, 2011;
Domino, Wells, & Morrissey, 2015; and DeVries et al., 2012), there is no current
research that examines the impact of PCMHs on ADHD medication adherence and
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parental ADHD medication beliefs. This study has positive social change implications as
PCMHs demonstrated they increase parental beliefs about adherence to ADHD
medication, which could lead to the increased parental adherence in the future. This
would potentially decrease the economic burden associated with increased healthcare and
education resource utilization and improve the quality of life of children with ADHD.
Additionally, this study extends the knowledge base of what is known about the impact
of PCMHs on treatment outcomes, particularly as it relates to parental medication
adherence and beliefs related to children with ADHD. Finally, this research may impact
healthcare policy created by agencies such as the Centers for Medicare and Medicaid and
the American Academy of Pediatrics that support PCMH enrollment for children with
ADHD and lead to increased patient access to PCMHs.
In Chapter 1, I discuss the background of the study, the major areas of research
related to the study, and the problem statement, and provide the research questions and
hypotheses. I elaborate on the theoretical framework and nature of the study in Chapters
2 and 3. I also discuss the study methodology, assumptions, scope and delimitations, and
limitations. The chapter concludes with the significance of the study and a summary of
the chapter.
Background of the Study
ADHD is a neurodevelopmental disorder that involves the inability to control
impulsive behaviors and includes difficulty with paying attention (CDC, 2013). Feldman
and Reiff (2014) reported that ADHD is most prevalent in boys, with boys also having a
greater proclivity to be diagnosed with combined type versus inattention only. The
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disorder is generally diagnosed during childhood, however researchers have asserted it
can also persist into adulthood (Feldman & Reiff, 2014). The Diagnostic and Statistical
Manual of Mental Disorders–5 (DSM-5) required that no fewer than five symptoms be
present in one or both domains prior to the age of 12 in order to receive an ADHD
diagnosis (American Psychiatric Association, 2013). At the point of diagnosis, treatment
such as behavior therapy and/or pharmacotherapy is generally prescribed.
Pharmacotherapy, particularly using stimulant medication, can be very effective
and is first-line pharmacotherapy for the treatment of ADHD (Weyandt et al., 2014).
Medication may provide children and adolescents with ADHD with a significant
opportunity to achieve long-term treatment success, including improved academic
performance, decreased deviant behavior related to poor peer and family relationships,
and fewer unintended injuries, if they adhere to the treatment regimen (Chacko,
Newcorn, Feirsen, & Uderman, 2010; McConaughy, Volpe, Antshel, Gordon, & Eiraldi,
2011; Murray-Close et al., 2010; Klein et al., 2012). Some side effects associated with
pharmacotherapy include changes in mood and personality, depression, and irritability
(Toomey et al., 2012).
Members of the medical community have generally categorized medication
adherence as patient related, medication related, and environment related (Ferrin &
Taylor, 2011). Key contributors to low medication adherence include parental attitudes
about medication, presence of side effects, perceived effectiveness, age, gender, race, and
socioeconomic status (SES; Brown & Bussell, 2011; Malaysia, 2010; Toomey et al.,
2012). Parental attitudes are an environmental factor on which this study will also focus.
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Brown and Bussell (2011) additionally reported that factors related to nonadherence of
urban and low socioeconomic patients are high medication costs as well as problems with
insurance and insurance coverage.
Ferrin et al. (2012) reported there is a difference between nonintentional
nonadherence and intentional nonadherence, stating factors such as low IQ, adverse
effects, and challenging drug regimens contribute to nonintentional nonadherence, while
environmental factors such as family or personal attitudes contribute to intentional
nonadherence. I focused this research more on intentional nonadherence to ADHD
medication and how parental attitudes and beliefs may impact their adherence to ADHD
medication in both PCMHs and non-PCMHs.
Parental perceptions toward ADHD medication are important, as parents are the
ones primarily responsible for making treatment and healthcare decisions for their
children (Charach & Fernandez, 2013). However, the amount of influence parents have
on their child’s decisions regarding medication adherence often diminishes as the child
ages (Chacko et al., 2010). Chacko et al. (2010) further posited that both the parent’s and
the child’s beliefs and attitudes around medication moderate medication adherence,
although it is the parent’s understanding of ADHD that determines whether the child
originally accepts stimulant medication. It is important for practitioners to focus their
efforts on helping parents understand ADHD, medication treatment options, and how
their child may benefit from adhering to the prescribed treatment regimen. Emphasis in
this area could potentially reduce the economic burden on the healthcare system and
diminish the social and academic impairment experienced by this population.
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The introduction of the PCMH in 1967 was designed to reduce resource
utilization and to address some of the above issues that affect children with special health
care needs (Sia, Tonniges, Osterhus, & Taba, 2004). PCMHs are pediatric or primary
care physician offices that approach care delivery through the provision of the following:
(a) patient-centered care, which includes compassionate and culturally sensitive care; (b)
comprehensive care, which includes services for mental health and chronic care; (c)
coordinated care, which includes communication between multiple providers and
services; (d) accessible care, which includes 24-hour, 7-day-a-week access to phone
and/or electronic records; and (e) care that is committed to quality, which includes
medication management (Patient-Centered Primary Care Collaborative, 2013). Health
care providers in PCMHs emphasize the patient as a whole and integrate other medical
and pharmacy personnel into the decision-making process of patient care. Additional
services offered in a PCMH include medication review, coaching and advice, and peer
support and encouragement to assist patients with their overall care experience.
The passage of the Patient Protection and Affordable Care Act in 2010 mandated
the implementation of PCMHs, which have been widely adopted throughout the United
States (Fields, Leshen, & Patel, 2010). Currently, there is no requirement for PCMHs to
be accredited by any organization. However the National Committee for Quality
Assurance (NCQA; 2014) recognized over 10% of primary care practices in the United
States as PCMHs. The increase in support of PCMHs and accreditation by these
organizations should lead to expansion of these types of medical practices, thus providing
more access to these valuable services. The five primary components of a PCMH may
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also prove to be an important way to address poor medication adherence in children with
ADHD, as there is no current literature that speaks to the impact of PCMHs on parental
beliefs about ADHD medication and parental medication adherence in this population.
This research may demonstrate that PCMHs improve parental attitudes and adherence to
ADHD medication and thus provide an effective model to improve patient outcomes and
decrease the health-related, academic, and social costs associated with ADHD.
Problem Statement
ADHD can lead to clinically significant academic impairment (e.g., low
standardized testing scores), decreased cognitive ability (e.g., low scores on full-scale IQ
testing), social impairment (e.g. poor family and peer relationships; Bussing, et al., 2012;
Express Scripts, 2014; McConaughy et al., 2011; Visser et al., 2014), an increased
occurrence of grade retention and failure to graduate (Robb et al., 2011), increased
emergency room visits, unintended injuries (Merrill, Lyon, Baker, & Gren, 2009;
Schwebel et al., 2011), parenthood at an early age (Barkley, Fischer, Smallish, &
Fletcher, 2006; Reimer, Mehler, D’Ambrosio, & Fried, 2010), poor peer and family
relationships that can lead to delinquent behavior, and greater likelihood to have
substance use disorder (Klassen, Miller, & Fine, 2004; Wilens et al. 2011). Additionally,
because ADHD can persist into adulthood, poorly managed ADHD symptoms can
adversely impact gainful employment due to the poor development of social skills
required for success, the inability to stay focused on tasks, and decreased cognitive
abilities.
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Medication may provide children and adolescents diagnosed with ADHD with a
significant opportunity to achieve long-term treatment success through symptom
management, including impulse control, increased concentration, decreased aggression,
and reduced hyperactivity and social withdrawal (Nijmeijer et al., 2008, Prasad et al.,
2013) if they adhere to the treatment regimen (Chacko et al., 2010). Reasons attributed to
medication adherence are patient-related (e.g. SES; Brown & Bussell, 2011), medicationrelated (e.g., efficacy; Barner, Khoza, & Oladapo, 2011), and environment-related (e.g.,
parental beliefs; Ferrin & Taylor, 2011, Garbe et al., 2012; Zetterqvist, Asherson,
Halldner, Långström, & Larsson, 2013). Dawood, Isham, Ibrahim, and Palaian (2010)
contended that for those children with chronic illness, the lack of parental understanding
of their child’s illness, reticence around therapy efficacy, and concern about adverse
effects of medication impact children’s adherence. Thus, parents have the largest impact
on their child’s medication initiation and adherence (Bai, Wang, Yang, & Niu, 2015).
Attempts to increase medication adherence include enhancing parental knowledge
and information regarding ADHD, educating parents on the safety and the social
acceptability of medication, behavior therapy, and psychoeducation (Bussing et al.,
2012). The literature reveals that while some of these interventions (psychoeducation
and behavior therapy) may have some incremental impact on increased medication
adherence in the short term, substantial increases in medication adherence remain a
challenge (Dean, Walters, & Hall, 2010; Hébert, Polotskaia, Joober, & Grizenko, 2013,
Sitholey, Agarwal, & Chamoli, 2011). Methods to reduce the economic loss, social
impairment, and poor clinical outcomes related to inadequate ADHD medication
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adherence is of significant importance to healthcare professionals and researchers
(Bussing, et al., 2012, Lehmann et al., 2014, Schwebel et al., 2011).
Brown and Bussell (2011) suggest that PCMHs should contribute to increased
medication adherence due to the type of patient-centered care delivered in a PCMH.
However, parental beliefs and attitudes can be a barrier to adherence and persistence.
Corkum, Bessey, McGonnell and Dorbeck (2015) argue parental perceptions of ADHD
as well as their acceptability of treatment options are the central barriers to medication
adherence. Researchers found when parents are provided with relevant information
around ADHD treatment, adherence to medication can be increased (Bai et al., 2015;
Corkum, Rimer, & Schachar, 1999). Current research indicates lack of knowledge about
ADHD and its treatment and poor emotional support are the primary obstacles for
medication initiation and persistence (Bai et al., 2015).
PCMHs have been shown to reduce pediatric resource utilization (DeVries et al.,
2012) and place emphasis on the patient as a whole. PCMHs also integrate other medical
and pharmacy personnel into the decision-making process of patient care and offer
services such as medication review, coaching and advice, and peer support and
encouragement to patients, which assist with their overall care experience. PCMHs can
provide improvements to health outcomes for those children with challenging medical
conditions such as ADHD, where care coordination is recommended (Knapp et al., 2012).
Fragmented health care, such as poor care coordination, limited access to care, limited
amount of time available for providers to spend with the patients, and inadequate
medication reconciliation of prescriptions from multiple providers create barriers to
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medication adherence (Brown & Bussell, 2011; Croghan & Brown, 2010). Knapp et al.
(2013) asserted that PCMHs are critical for children with mental health conditions, which
can impact the entire family. Toomey, Homer, and Finkelstein (2010) not only found
disparities related to the diagnosis and treatment of children with mental health disorders,
they also reported disparities between mental health disorders and medical home
attainment. The investigators found the likelihood of children with ADHD to have a
PCMH was lower than that of children with asthma; which is a chronic medical
condition. This finding indicates children with mental health conditions, such as ADHD,
may be missing out on the benefits of PCMHs and the potential for improved outcomes.
Therefore, PCMHs were evaluated in this study to assess their influence on parental
beliefs about ADHD medication (benefits vs. risks) and their adherence to ADHD
medication.
Purpose of the Study
The purpose of this quantitative study was to determine if PCMHs have a
significant impact on parental beliefs related to ADHD medication and parental ADHD
medication adherence. To address this gap, I conducted a quantitative study to survey
parents of children with ADHD who do and do not have a PCMH and assess parental
beliefs regarding ADHD medication (risks vs. benefits) and their adherence to prescribed
ADHD medication. I utilized questions from 2007 National Survey of Children’s Health
(NSCH; Toomey, Chan, Ratner, & Schuster, 2011) to determine what type of provider
the parent has chosen for their child’s care (PCMH or non-PCMH). The Beliefs About
Medicines Questionnaire (BMQ; Horne, Weinman, & Hankins, 1999) and the Morisky
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Medication Adherence Scale (MMAS–8; Morisky, Ang, Krousel-Wood & Ward, 2008))
were utilized in this study to assess parental beliefs about ADHD medication and their
adherence to ADHD to medication. The following covariates were evaluated for
inclusion in the study: age, ethnicity, gender, SES, education, geographic location, and
parent’s own experience with taking ADHD medication.
Research Questions and Hypothesis
RQ1: Is there a difference in parental beliefs about ADHD medications (benefits
vs. risks) as measured by the BMQ–Specific between PCMH and non- PCMH
groups?
H01: There is no significant difference in parental beliefs about ADHD
medication (benefits vs. risks) between PCMH and non-PCMH groups.
Ha1: There is a significant difference in parental beliefs about ADHD
medication (benefits vs. risks) between PCMH and non-PCMH groups.
RQ2: Is there a difference in parental adherence to ADHD medication as
measured by the MMAS–8, between PCMHs and non-PCMH groups?
H02: There is no significant difference in parental adherence to ADHD
medication between PCMH and non-PCMH groups.
Ha2: There is a significant difference in parental adherence to ADHD
medication between PCMH and non-PCMH groups.
Theoretical Framework
I used the theory of planned behavior (TPB; Ajzen, 1991) as a theoretical
framework for this study because parental beliefs and attitudes around ADHD and its

11

treatment directly impact their children’s medication-taking behavior. When parents
perceive there are positive psychosocial benefits to stimulant medication, their children
also perceive greater psychosocial benefits to medication (Hebert et al. 2013). This may
impact children’s beliefs around ADHD medication, which have been shown to directly
impact how they choose to manage their illness (Ferrin & Taylor, 2011).
I used the TPB, an extension of the theory of reasoned action (Fishbein & Ajzen,
1975), to better understand parent’s beliefs and attitudes toward ADHD and how those
beliefs may impact their child’s intention to adhere to medication. The theory asserts the
intention of a person to perform a specific behavior is a reflection of the motivational
influences on that behavior (Ajzen, 1991). The three components that influence
behavioral intention are: a) attitude, b) subjective norm, and c) perceived behavioral
control. Ajzen (1991) posits that the stronger a person’s intention to engage in a
behavior, the higher the probability that the behavior will occur. Subjective norms are
indicative of a person’s beliefs related to how individuals in their social network perceive
the behavior in question. A person’s belief in their ability is referred to as their perceived
behavioral control (Azjen, 1991). Therefore, the more positive a person’s attitude and
subjective norm, the greater that person’s perceived control and the higher the likelihood
of the person’s intention to perform the targeted behavior. This theory helped to explain
the effectiveness of PCMH’s to impact parental beliefs and attitudes around ADHD and
it’s treatment, which can lead to positive medication-taking intention of their children.
This theory helped to provide context for the research questions from the BMQ–Specific,
which are directly related to parent’s beliefs/attitudes about ADHD medication and are
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linked to behavioral intention. It also provides context for the MMAS–8, which queries
parent’s actual adherence to ADHD medication for their children and is the targeted
behavior for this research.
Several other theories have been used in the literature to explain medication
taking behavior that were considered for this study: the illness career model (Biddle,
Donovan, Sharp, & Gunnell, 2007), the trans-theoretical model of change (Prochaska &
DiClemente, 1984), the health belief model (Hochbaum, Rosenstock, & Kegels, 1952),
social exchange theory (Hamrin, McCarthy, & Tyson, 2010), and the unified theory of
behavior change (UTB; Jaccard, Dodge, & Dittus, 2002). Each of these theories suggests
different factors that contribute to medication adherence; however, the TPB was the best
fit for this research. I discuss the theoretical framework further in Chapter 2.
Nature of Study
The nature of this study was quantitative and utilized a self-report survey
administered via Qualtrics to determine if PCHMs influenced parental beliefs about
ADHD medication (benefits vs. risks) and their adherence to ADHD medication. I chose
this design because only a quantitative design can test statistical differences between
groups. I had one subject variable (PCMH) and two dependent variables (parental beliefs
about ADHD medication and parental ADHD medication adherence). A multivariate
analysis of variance (MANOVA) was used to analyze the data using the SPSS 24.0
software package. A quantitative survey was the most effective method to obtain this
data because it allowed me to capture data from a large representative sample of parents
who have children with ADHD while also allowing the participants to remain
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anonymous. The target population was parents with children between the ages of 5 and
12 who had been diagnosed with ADHD and who had been prescribed ADHD
medication for at least three months. This age range was selected because parents are
largely responsible for administering medication to their children up to age 12. As
children age, they tend to have more influence on their own medication taking behavior.
Prior to age 5, behavior therapy is recommended as the first-line approach according to
the American Academy of Pediatrics.
Definition of Terms
Medication adherence: The degree to which a person’s behavior matches the
agreed recommendations from a health care practitioner, including following diet and
lifestyle changes as well as taking medication (World Health Organization, 2003).
Patient-centered medical home (PCMH): A pediatrician’s or primary care
provider’s office that provides the following care components: (a) patient-centered care,
(b) comprehensive care, (c) coordinated care, (d) accessible care, and (e) commitment to
quality and safety (Patient-Centered Primary Care Collaborative, 2015).
Benefits: Refers to necessity as described in the BMQ–Specific scale.
Risks: Refers to concerns as described in the BMQ–Specific scale.
Attention deficit/hyperactivity disorder (ADHD): A continued pattern of
hyperactivity-impulsivity and/or inattention that impedes a person’s ability to function or
develop, with symptoms that present in at least two settings (e.g. school, home, with
friends or family) and adversely impacts occupational, school, or social functioning.
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Multiple symptoms must be evident before the age of 12 (American Psychiatric
Association, 2013).
Assumptions
This study was based on several assumptions. Firstly, I assumed that the parents
who participated in the survey would answer the questions honestly and accurately.
Secondly, I assumed the questions from the BMQ, which were used to assess parent’s
beliefs and attitudes around ADHD, were a valid and reliable measure of parental beliefs
and attitudes. Thirdly, I assumed the questions utilized from the MMAS-8, which were
used to assess parents’ adherence to ADHD to medication, were a valid and reliable
measure of children’s intention to adhere to medication. Additionally, I assumed that the
parent’s responses accurately reflected their beliefs about ADHD medication and their
adherence to their child’s prescribed ADHD medication. I also assumed that the parent’s
responses to the questions from the 2007 NSCH survey accurately depicted the type of
medical provider they utilized for their child’s healthcare. Lastly, I assumed that the
survey participants reflected an ample sample size for both parents with a PCMH and
parents without a PCMH. The above assumptions increased the study reliability and
external validity. In the following section I discuss the scope and delimitations of the
study.
Scope and Delimitations
The scope of this quasi-experimental research included parental responses to
survey questions related whether or not they utilized a PCMH for their child’s healthcare,
questions related to their own beliefs and attitudes around ADHD medication, and
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parent’s responses to questions related to their adherence to their child’s ADHD
medication. To be included in the survey, parents must have had a child with ADHD,
between the ages of 5 and 12 for whom ADHD medication had been prescribed for the
previous 3 months. Potential generalizability may be impacted based on the variation in
the sample of parents on the demographic variables in both groups.
I utilized the TPB, which was the theoretical framework for this study, to provide
context to the two research questions around parental beliefs and attitudes and the
influence of these beliefs on the parent’s adherence to medication. The TPB also served
as the basis to analyze the survey results and represented the motivational influences that
impacted the parent’s intention to follow the medication-taking regimen prescribed by a
healthcare practitioner.
I chose the focus of this study because it could possibly demonstrate that PCMHs
positively impact parental beliefs/attitudes related to ADHD medication and improve
parental adherence to ADHD medication for their children. These findings may support
the belief that PCMHs improve ADHD treatment outcomes for children and thus advance
the role of PCMHs as a viable option to improve medication adherence for this
population. Increased medication adherence for children with ADHD could potentially
decrease academic and social impairment, healthcare utilization, substance use, and risky
behaviors, all of which are detrimental to children’s long-term success.
Limitations
Limitations for this study were that self-report scales fundamentally have some
level of inaccuracy as a result of self-report bias, such as inaccurate participant memory
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recall and social desirability bias, or the desire of participants to give the “right” answer
versus the true answer (Voils, Hoyle, Thorpe, Maciejewski, & Yancy, 2011). Voils et al.
(2011) further reported measures that utilize self-report could have inadequate reliability,
with up to 20% lower rates than those obtained by other means. However, this research
provided an opening statement for both the MMAS–8 and BMQ–Specific scales that
explained that there was no right or wrong answer and other people have reported the
listed responses. That may have quelled some of participants’ desire to provide a
particular answer, but it would not likely have impacted memory recall. To address this
bias, most of survey questions asked participants to only think back as far as the last two
weeks, which should help reduce the issue of memory recall. Researcher bias, such as
leading questions or wording bias, was not likely be a factor in this research because the
survey was administered online, it was anonymous, and it utilized two validated
instruments to obtain the research data.
Race/ethnicity can also impact the accuracy of the results (Ramírez, Ford, &
Stewart, 2005), as different ethnic groups may vary in their interpretation of questions,
leading to survey misclassification (Ramírez et al., 2005). The consent form indicated
that participant responses were3 anonymous, which may have contributed to more
accurate parental responses and reduced social desirability bias. The subject variable
(PCMH) was not randomly assigned, as each group self-selected based on their responses
to the PCMH survey questions. This nonrandom assignment can impact internal validity
as a result of nonequivalent groups in the study. Participant ethnicity was captured on the
demographic questionnaire, which helped to isolate the potential impact of this factor in
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participant responses. Using the validated instruments (BMQ–Specific and MMAS–8) to
assess parental beliefs and medication adherence, as well as appropriate participant
selection via inclusion criteria, minimized potential researcher bias.
Some of the questions utilized in the 2007 NSCH to determine whether the child
has a PCMH may not apply, therefore, it may be difficult to accurately determine PCMH
status. For example, some parents may not have had the need for a referral; therefore,
they would respond to the question as “not applicable.” Although the survey questions
utilized to determine PCMH status have some gaps and may impact accurate selection of
PCMH status by the parent, this is the current and most widely used method in other
national studies (Boudreau, Goodman, Kurowski, Perrin, & Cooley, 2014; DuPaul,
Carson, & Fu, 2013; Knapp et al., 2012; Knapp et al., 2013; Raphael et al., 2015;
Strickland, Jones, Ghandour, Kogan, & Newacheck, 2011; Toomey et al., 2011) to
determine PCMH status. The use of the 2007 NSCH survey questions also allow for
study comparison and mirrors the American Academy of Pediatrics determination of a
PCMH status.
Clustering may be a limitation if significant portions of data are derived from the
same part of the country where large PCMH medical groups are more or less prevalent.
Clustering refers to the idea that a large group of respondents utilize the same medical
provider, provider group, or reside in a part of the country where there are a high number
of PCMHs or there are very few medical homes. This factor can impact external validity,
leading to the inability to generalize the results to the greater population. The
demographic questionnaire (see Appendix A) asked parents to identify the state in which
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they live, thus making it easier to identify if responses are clustered in a specific state or
region. In addition to the above potential geographical confounder, other possible
confounders include age, ethnicity, gender, and parent’s own previous experience with
ADHD medication. Each of these factors was controlled for and contained in the
demographic questionnaire in the event the data revealed they needed to be considered in
the analysis.
Significance of the Study and Implications for Social Change
This research contributes to the scholarly literature available on PCMHs and will
fill a gap in literature by determining if PCMHs positively impact parental beliefs and
attitudes around ADHD and medication, which is associated with increased medication
adherence for children with ADHD. Symptoms associated with ADHD are important
risk markers for future life challenges (Caye et al., 2016); thus, medication adherence can
contribute to long-term educational, psychosocial, and mental health well-being and
maximize outcomes (Charach & Fernandez, 2013). This research is also important for
those who make policies regulating healthcare and agencies who influence those policies.
Some of these agencies include: the American Academy of Pediatrics, which influences
healthcare policy; the NCQA, which awards recognition to PCMH; the Joint
Commission, which provides PCMH accreditation; and Centers for Medicaid and
Medicare Services, which intends to offer PCMH designation to assist in payment
reimbursement. These policy-making organizations could make it a recommendation that
all children diagnosed with ADHD attain access and receive treatment in a PCMH. A
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policy change of this magnitude could significantly reduce the financial burden
associated the increased academic and healthcare services required by this population.
This study has positive social change implications as it provides valuable
outcomes data on PCMHs, which may support the hypothesis that parental
beliefs/attitudes about their child’s ADHD medication can be positively influenced by
PCMHs. This data is also important as a measure of PCMH effectiveness in improving
outcomes and whether they are meeting the goals as mandated in the Affordable Care
Act.
Summary and Transition
Chapter 1 provided an overview of ADHD, medication adherence in children with
ADHD, the influence of parental attitudes on medication adherence, and the role of
PCMHs and their impact on health outcomes for children with chronic conditions. I also
discussed the research questions, hypotheses, methodology, assumptions and limitations.
Chapter 2 provides a detailed literature review on these topics as well as the theoretical
framework that was utilized in this study.
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Chapter 2: Literature Review
Introduction
This chapter presents a review of relevant scholarly literature around PCMHs,
medication adherence, ADHD, parental beliefs/attitudes related to ADHD medication,
and TPB. The problem that is explored is the high rate of medication nonadherence in
children with ADHD and the impact of PCMHs on parental beliefs about ADHD
medication and ADHD medication adherence. ADHD has many consequences, which
include clinically significant academic and social impairment (Bussing et al., 2012;
Express Scripts, 2014; Visser et al., 2014), an increased occurrence of grade retention and
failure to graduate (Robb et al., 2011), risky sexual behaviors (Flory, Molina, Pelham,
Gnagy, & Smith, 2006), substance use disorder (Wilens et al., 2011), poor quality of life
(Danckaerts et al., 2010), peer rejection (Murray-Close et al., 2010), parenthood at an
early age (Barkley et al., 2006; Reimer et al. , 2010), and increased rates of incarceration.
Nonadherence to medication has been shown to contribute to healthcare
utilization, (Cutler &Everett, 2010; Hamilton, Lerner, Presson & Klitzner, 2013;
McGrady & Hommel, 2013; Toomey et al., 2011), particularly for children with ADHD.
Unintended injuries due to risky behavior and mental health service utilization are key
consequences that directly impact healthcare utilization. Care provided in a PCMH has
been associated with a reduction in healthcare utilization and improved outcomes
(Toomey et al., 2011). Therefore, the purpose of this study was to determine if PCMHs
have an impact on parental beliefs related to ADHD medication and ADHD medication
adherence.
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Literature Search Strategy
The literature review search strategy included a digital search of peer-reviewed
literature through the Thoreau Multi-Database Search, Google Scholar, PsychINFO,
PsychARTICLES, and EBSCOhost. The literature search was focused on the last five
years (2011–2016); however, a complete and exhaustive review was conducted, which
also included the seminal literature. The primary search terms included: attention-deficit
hyperactivity disorder (ADHD), mental health, medication adherence, behavioral health,
medication compliance, medication persistence, patient-centered medical homes, medical
homes, the theory of planned behavior, medication adherence theories, parental beliefs
and medication, parental attitudes toward medication, parental beliefs or attitudes about
medication, attitudes about ADHD, beliefs about ADHD, intention to adhere, parents and
intention to adhere to medication, role of genetics in ADHD, genetic influences in
ADHD, cognitive behavior therapy, behavior therapy, behavior therapy effectiveness,
psychostimulants, and ADHD medication. Term combinations included ADHD and
medication adherence, ADHD and genetics, ADHD and patient-centered medical hones,
ADHD and the theory of planned behavior, medication adherence and the theory of
planned behavior, ADHD and beliefs about medication, ADHD and medication, patientcentered medical homes and medication adherence, and patient-centered medical homes
and parental attitudes. I highlighted the definition of patient-centered medical homes,
the recent research and findings pertaining to PCMHs and medication and ADHD, the
factors that impact medication adherence and the relationship to clinical outcomes, the
influence of parental beliefs on intention to adhere to medication, ADHD research and
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the use of the theory of planned behavior as the theoretical framework, and the literature
regarding the use of self-report in research.
Theoretical Framework
A variety of theoretical models have been utilized to understand reasons for
medication nonadherence, including the illness career model (Parsons, 1951), the transtheoretical model of change (Prochaska & DiClemente, 1984), the health belief model
(Hochbaum et al., 1952), the social exchange theory (Emerson, 1976), UTB (Jaccard, et
al., 2002), and TPB (Ajzen, 1991). The TPB was utilized as the framework for this
study. However, I have included a brief summary of the preceding theories to elucidate
the various approaches utilized in the literature to understand medication-taking behavior.
The Illness Career Model
The illness career model asserts people apply a social process to help-seeking
behavior, which can be impacted by the patient’s geography or social living environment
(Biddle et al., 2007). Patients will consult with those outside of the medical community,
including family, friends, and others in their social network to assist with their medicalrelated decision-making. The advice obtained from the social circle may go against
medical advice and be perceived as irrational by medical practitioners (Charach, Volpe,
Boydell, & Gearing, 2008). Moses (2011) suggested psychiatric treatment acceptability
is influenced by peer socialization. Those youth who have peers in their circle who also
receive psychiatric treatment tend to be more accepting of their own psychiatric
treatment. Therefore, this framework has been utilized to understand how parents
influence children’s adherence to medication (Potter, 2013). This framework does fall in
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line with the theoretical approach of this study, which asserts that beliefs and attitudes of
those in a person’s sphere of influence impact medication adherence, and would also be
an appropriate theory for this study. However, this research placed additional emphasis
on the role of parental beliefs and their influence on medication adherence.
The Trans-Theoretical Model of Change
The trans-theoretical model of change focuses on a person’s readiness to change
and contends behavior change occurs in the following stages: (a) pre-contemplation,
where the person is not interested in making any behavioral changes in the near future;
(b) contemplation, where the person considers making behavioral changes within the
upcoming six months, but the change has not been initiated; and (c) preparation, where
the person has implemented steps toward making the change within the next 30 days, an
indicator that change is eminent (Prochaska & DiClemente, 1984); (d) action, where the
person has successfully made and maintained the behavior change for under 6 months;
and (e) maintenance, where the behavior change has been implemented for more than 6
months (Prochaska & DiClemente, 1984). People may often vacillate among the stages
and not progress straight through from precontemplation to maintenance (Prochaska &
DiClemente, 1984). Thus, regression can occur throughout the change process.
Medication adherence would not be considered sustained until the person reached the
maintenance stage of this model.
As reported in Watkins (2015), Charach et al. (2008) indicated medication
adherence happens between the stages of action and maintenance and suggested while
trying alternative treatments, some family members may need time to accept the
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psychiatric diagnosis. This theory was not a fit for this research because it does not
account for the influence of the beliefs and attitudes of parents on behavior change or the
general impact of other factors that influence a person’s decision to take action.
The Health Belief Model
The health belief model, which is considered one of the most frequently used
theories related to health behavior (Orji, Vassileva, & Mandryk, 2012), has been utilized
to explain behavior related to illness and prevention. The focus of the model is related to
motivation and a person’s perceptions, modifying behavior, and the likelihood that they
will take action (Hochbaum et al., 1952). The five factors of the health belief model that
impact a person’s motivation and action-taking behavior are: (a) perceived susceptibility,
a persons’ perception of the odds of developing a condition that negatively impacts their
health; (b) perceived severity, a persons’ belief as to the life effect the condition will
have; (c) perceived benefit of taking action, a person’s belief that the condition is serious
enough to warrant action, and the type of action taken is influenced by effectiveness of
the available options; (d) barriers to taking action, in which persons may believe that they
should take action but factors such as cost and inconvenience can adversely impact the
follow-through with the action; and (e) cues to action, including internal and external
triggers that prompt a person to action, which most likely occurs in the absence or
elimination of barriers (Hochbaum et al., 1952). This model also places emphasis on a
persons’ beliefs; however, it does not address how others’ beliefs and attitudes impact
behavior.

25

Social Exchange Theory
Social exchange theory holds that people make decisions based on their ability to
exchange and maximize resources and rewards and minimize costs (Hamrin et al., 2010).
In other words, individuals assess the advances they can achieve through a reciprocal
relationship. It is assumed that the individual or group is rational and is able to make
rational decisions when contemplating the resource exchange. Hamrin et al., (2010)
assert this theory can be applicable to families as they examine the potential benefits and
alternatives to pharmacological treatment for their child who has a behavioral health
diagnosis. This theory also supports the premise that previous parental experience with
mental illness and favorable use of psychotropic medication is correlated with parents’
willingness to entertain psychotropic medication for their child (Hamrin et al., 2010).
This theory of parental attitudes toward medication and mental health diagnosis could be
applicable to this research, but this research will not evaluate the reciprocal relationship
as a variable for adherence.
Unified Theory of Behavior
UTB is a commonly used theory in the literature regarding the influences of
behavior (Jaccard, et al., 2002). The UTB focuses on two dimensions. The first involves
a person’s behavior, which is influenced by the person’s knowledge and skills for
behavioral performance, environmental restrictions, intention or decision to perform
behavior, importance of behavior, and habit and spontaneous processes (Guilamo-Ramos,
Jaccard, Dittus, Gonzalez, & Bouris, 2008; Olin et al., 2010). The second dimension
involves those components that impact a person’s intention, emotions, social norms, self-
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concept, expectancies, affect, and self-efficacy (Guilamo-Ramos et al., 2008; Olin et al.,
2010). Based on this theory, it is believed that even if a person’s intentions can be
influenced to participate in a specific behavior, behavioral action may not occur until the
first set of factors (i.e. environmental barriers or constraints, knowledge) are addressed
(Olin et al., 2010). This theory does address intention and attitudes as factors that
influence behavior, and the impact of environmental barriers such as knowledge and
parental attitudes. Thus, this theory could also be an option for this research.
Theory of Planned Behavior
TPB is an extension of the theory of reasoned action and was selected for this
research (Fishbein & Ajzen, 1975). The theory asserts the intention of a person to
perform a specific behavior is a reflection of the motivational influences on that behavior
(Ajzen, 1991). According to Ajzen, the three components that influence behavior are:
(a) attitude, (b) subjective norm, and (c) perceived behavioral control. Ajzen further
posits that the stronger a person’s intention to engage in a behavior, the higher the
probability that the behavior will occur. Subjective norms are indicative of a person’s
beliefs related to how individuals in their social network perceive the behavior in
question. A person’s belief in their ability is referred to as their perceived behavioral
control (Azjen, 1991). Therefore, the more positive a person’s attitude and subjective
norm, the greater the person’s perceived control as well as the likelihood of the person’s
intention to perform the targeted behavior.
The TPB is a popular theory utilized to investigate medication adherence for
diverse ethnicities including Latinos, Caucasians, and African Americans, with chronic
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diseases and conditions including pain, cardiovascular disease, depression, and diabetes.
Laba, Lehnbom, Brien, and Jan (2015) suggested intention plays an important role in
medication adherence in chronic illnesses. Lewis, Askie, Randleman, and SheltonDunstan (2010) found friends and family influenced beliefs and the behavior, which were
correlated with medication adherence in African American participants. Several
researchers found medication adherence was strongly associated with attitudes, social
support/ social circle, and family (Ahmed & Aslani, 2013; August & Billmek, 2015;
Charach & Fernandez, 2013, Cutler & Everett, 2010; Hébert et al., 2013; Luga &
McGuire, 2014; Vissman, Young, Wilkin, & Rhodes, 2013). Charach and Fernandez
(2013) asserted parents’ beliefs and attitudes related to ADHD treatment significantly
impact medication initiation. However, some parents do not accept medication as an
appropriate choice to treat their child’s ADHD-related behaviors. Other parents evaluate
the potential of social disapproval and possible adverse effects of ADHD medications as
the reason for forgoing medication initiation (Bussing et al., 2012; Toomey et al., 2012).
Social acceptability/social norms are popular themes associated with medication
adherence and are a construct of the TPB. Charach and Fernandez (2013), and Hébert et
al. (2013) reported increased parental feelings and attitudes related to medication social
acceptability coincide with their increased willingness to accept pharmacological options.
Ludwig et al. (2011) compared individuals who live in disadvantaged and those who live
in affluent neighborhoods. They found those who reside in low-income neighborhoods
are more likely to experience poor social cohesion, which may perpetuate norms that
reduce good health behaviors.
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Pillow, Naylor, and Malone (2014) utilized the TPB to evaluate the beliefs about
stimulant medication of college students with ADHD. The study focused on the general
attitudes of current and past stimulant medication users and proposed that people acquire
and alter their beliefs related to stimulants due to their connections with others. They
further contend that familiarity with and the experience of those who take stimulant
medication can influence medication adherence. Pillow et al. (2014) further reported the
constructs of the TPB (attitudes, perceived control, social norms) may possess clinical
and predictive value due to the significant differences found in the general attitudes
related to stimulant use, the perception of control, and the opinions of others around the
use of stimulants.
Bai et al. (2015) utilized the constructs of the TPB in the design of
psychoeducational programs for parents of children with ADHD. Parents were divided
into a control group or an intervention group where their ADHD knowledge, TPB
components, and children’s ADHD symptoms were assessed. Bai et al. found that
interventions, which used the TPB model effectively, improved adherence behavior and
ADHD symptoms. Their research revealed that inaccurate disease state and treatment
associated knowledge, poor emotional support, and feelings of isolation were the primary
barriers to medication initiation and persistency among newly medicated patients.
Strecher, De Vellis, Becker, and Rosenstock (1986) reported self-efficacy is
correlated with a person’s beliefs around their capabilities to execute specific behaviors
in certain situations. Thus, one’s self-efficacy can vary greatly depending on the
situation or task. Time on task and the amount of effort expended is also affected by self-
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efficacy (Strecher et al., 1986). This may have an impact on ADHD medication
adherence and persistence as inappropriate effort in understanding the need for ADHD
medication and treatment may lead to poor adherence with the prescribed medication
regimen. Based on the presented research and the utilization of the TPB in multiple
health behavior studies, this theory was chosen as the best fit for this study and will
provide context to the two research questions around parental beliefs and attitudes, and
the influence of these beliefs on parent’s adherence to medication. The TPB also serves
as the basis to analyze the survey results, and represents the motivational influences that
impact the parent’s intention to follow the prescribed medication-taking regimen by a
healthcare practitioner. Data related to this contention was collected via the BMQ–
Specific and MMAS–8 surveys, which may support or challenge this theory. The results
of this study may demonstrate that PCMHs positively impact parental beliefs/attitudes
related to ADHD medication and improve parental adherence to ADHD medication for
their children. This is important because it may support the belief that PCMHs improve
treatment outcomes and thus advance the role of PCMHs as a viable option to improve
medication adherence for this population. Increased medication adherence for children
with ADHD could potentially decrease academic and social impairment, healthcare
utilization, substance use, and risky behaviors; all of which are detrimental to children’s
long-term success.
Attention-Deficit Hyperactivity Disorder
The CDC reports approximately 10% of children in the United States have been
diagnosed with ADHD (Centers for Disease Control and Prevention [CDC], 2013). New
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data suggests the overall cost of ADHD, in both children and adults, is high as $266
billion dollars (Children and Adults with Attention Deficit/Hyperactivity Disorder, 2016)
as ADHD can persist into adulthood. ADHD is a neurodevelopmental disorder that
involves the inability to control impulsive behaviors and includes difficulty with paying
attention (CDC, 2013). ADHD can lead to clinically significant academic and social
impairment (Bussing, et al., 2012; Express Scripts, 2014; Visser et al., 2014), an
increased occurrence of grade retention and failure to graduate (Robb et al., 2011),
increased emergency room visits and unintended injuries (Merrill et al., 2009; Schwebel
et al., 2011), increased risk of unsafe driving, suicidal behavior, eating disorders and
parenthood at an early age (Barkley et al., 2006; Reimer et al., 2010). Medication may
provide children and adolescents with ADHD with a significant opportunity to achieve
long-term treatment success if they adhere to the treatment regimen (Chacko et al., 2010).
Visser et al. (2015) found just over 74% of children with ADHD, between the ages of 4
and 17, had taken medication, however, ongoing adherence to medication treatment
presents a challenge and contributes to the above detailed adverse impact of ADHD. As
reported earlier, up to 87% of children are non-adherent to medication (Ahmed & Aslani,
2013).
Etiology/Genetics
There is a strong correlation between the involvement of multiple genes in the
serotonin and dopamine pathways and ADHD, with approximately 76% of ADHD
occurrences having a link to genetics (Farrone & Mick, 2010). Neurotransmitter
dysregulation, particularly in serotonergic, dopaminergic, and noradrenergic gene
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systems have been commonly hypothesized to be involved in ADHD (Banaschewski,
Becker, Scherag, Franke, & Coghill, 2010). This hypothesis is supported by the
effectiveness and significant therapeutic effects of stimulant medications, the role of
dopamine in ADHD (Del Campo, Chamberlain, Sahakian, & Robbins, 2011) and
serotonergic genes which have been implicated in impulsivity (Banaschewski et al.,
2010). Other researchers have postulated that the exposure to maternal cigarette smoke
while pregnant and the exposure to lead may create a genetic predisposition to ADHD
(Braun, Kahn, Froehlick, Auinger, & Lanphear, 2006; Froehlich, Anixt et al., 2011).
There is also some evidence that ADHD is the result of prefrontal-striatal circuitry
dysfunction however, limited information is available to support this theory (Dickstein,
Bannon, Castellanos, & Milham, 2006).
Researchers have additionally reported that there are age-related differences in the
genetic and neurocognitive mechanism theory. Thissen et al. (2015) argue that age is a
contributing factor to these variations, as gene expression can change during different
developmental stages. Larsson, Lichtenstein, and Larsson (2006) reported ADHD-related
hyperactivity and impulsivity decrease with age, and neurocognitive ability associated
with genetic effects escalates with age (Polderman et al., 2007). Thissen et al. (2015)
also found differences in a particular dopamine receptor allele and serotonin transporter
between adults and adolescents lending further support to this theory. Wilcutt (2005)
reported in the over 10,000 twin studies conducted to evaluate the etiology of ADHD, all
studies found genetics were associated with the individual variations in ADHD
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symptoms. Wilcutt further reported environmental influences accounted for the
disparities in ADHD symptoms.

Diagnosis
Diagnosis and initial treatment for ADHD most frequently occurs when children
are between the ages of seven and nine, or elementary school-aged, although the
development of ADHD occurs before then (Charach et al., 2011). ADHD is defined as:
a continued pattern of hyperactivity-impulsivity and/or inattention that impedes a
person’s ability to function or develop, with symptoms that present in at least two settings
(e.g. school, home, with friends or family), and adversely impacts occupational, school,
or social functioning. Multiple symptoms must be evident before the age of 12 (5th ed.;
DSM-5; American Psychiatric Association, 2013). Additionally, parents and or teachers
must provide information regarding the child’s symptoms to substantiate an ADHD
diagnosis (Feldman & Reiff, 2014). Charach et al. (2011) reported elementary schoolaged children are twice as likely to be diagnosed with ADHD as adolescents, with boys
representing the majority of incidences. Boys are also more likely to present with
combined type (inattention and hyperactivity) versus inattention only symptoms
(Feldman & Reiff, 2014). The severity of ADHD symptoms tend to decrease as children
age, however, most children still experience symptoms as adolescents (Charach et al.,
2011). Symptoms can also persist into adulthood and it has been reported that up to one
third of all children diagnosed with ADHD also have symptoms in adulthood (Barbaresi
et al., 2013). Many interventions have been utilized to address the symptoms of ADHD,
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including psychopharmacology, behavioral interventions, and a combination of both.
Unfortunately, researchers report the success of these interventions, even in combination;
have been suboptimal (Murray et al., 2008). Of important note, the diagnosis of ADHD
is often comorbid with other mental health diagnoses, particularly conduct disorder and
oppositional defiant disorder, with occurrence rates as high as 50% (Nijmeijer, Minderaa,
Buitelaar, Mulligan, Hartman, & Hoekstra, 2008). This high incidence of comorbidity
can contribute to complexity and morbidity of ADHD.
Adverse Impact of ADHD
Academic achievement. Children with an ADHD diagnosis often experience
academic difficulty and decreased academic achievement. Robb et al. (2011) reported
there is a significant impact on the costs associated with special education services for
children (kindergarten to 12th grade) with ADHD compared to those without. The
average cost per year for a child with ADHD was $4,181 vs. $211 for a child without
ADHD. Grade retention also occurred significantly more often with the ADHD group
(M = .40) vs. the non-ADHD group (M = .08), with an average cost per year of $222 vs.
$43 for the non-ADHD group. Lastly, Robb et al. reported children and adolescents
diagnosed with ADHD had a significantly greater report of behavioral misconduct
resulting in academic suspensions, discipline, or expulsion. The average cost for the
ADHD group was $604 annually vs. $63 for the non-ADHD group. The aggregate cost
of all three (special education, behavioral misconduct, and grade retention comes to a
total of $5,007 annually, which does not include the regular annual costs associated with
education, according to Chambers, Shkolnik and Perez (2003) of $7,793.
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Masseti et al. (2008) evaluated 255 children (125 diagnosed using modified
criteria for ADHD) over a period of eight years to assess academic performance.
Impairment was measured based on parent and teacher report as well as several of
instruments that evaluated achievement in various academic categories. The researchers
found children who exhibited the inattentive subtype of ADHD experienced decreased
academic performance. Bauermeister, Barkley, Bauermeister, Martínez, and McBurnett
(2012) also supported the contention that inattention is associated with academic
impairment. Lahey and Willcutt (2010) found children with ADHD exhibited poorer
academic performance on standardized testing, and Power et al. (2012) found homework
also to be a challenge for this population. Marshall, Evans, Eiraldi, Becker and Power
(2014) reported homework challenges include low energy, slow task completion, mind
wandering, and muted alertness and should be the target of interventions.
In a study of 178 children between the ages of 6 to 11, McConaughy et al. (2011)
found as many as 55% of children with ADHD experienced a clinically significant deficit
in Academic functioning, as demonstrated by lower scores on standardized and academic
tests as well as teacher ratings of performance, when compared to children without
ADHD. These scores included teacher ratings of child performance at grade level, child
effort, and academic motivation and ability. The researchers suggested that interventions
are needed to not only address the academic impairment experienced by these children,
but also there is a need for interventions to address the primary symptoms of ADHD, of
which includes the implementation and adherence to medication.
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Social impairment. Social impairment is a common hallmark of ADHD.
McConaughy et al. (2011) found up to 85% of children experienced clinically significant
social behavior impairment, which included decreased participation in social
organizations, sports, less friends, and more difficult relationships with family and peers.
Nijmeijer et al. (2008) reported peer rejection could occur as a result of the disruptive and
aggressive behaviors commonly exhibited by children with ADHD. And unfortunately,
children who display these behaviors can be unaware of the adverse effect they have on
others and therefore, are oblivious to their own unpopularity with peers. But not all
children with ADHD demonstrate aggressive behaviors. Nijmeijer et al. (2008) reported
some youth could become socially withdrawn, passive, shy, and display anxiety, which
leads to poor relationship development with peers. Bagwell, Molina and Pelham (2001)
found children with ADHD had fewer friends and were rejected more frequently
compared to those children without ADHD. Murray-Close et al. (2010) reported peer
rejection is very challenging to reverse and can impede children from acquiring important
developmental skills necessary for the successful navigation of life. They further assert
children might display an exaggerated self-concept that is off-putting to peers, leading to
rejection. Hoza et al. (2010) asserted the rejection that is experienced as a result of this
over-confidence could lead to aggression. Therefore, there appears to be a cycle of peer
rejection and aggression, one contributing to the other, which ultimately impedes
behavior change.
The trajectory of antisocial behavior in children with ADHD has been reported to
take two different paths: the first which can begin during preschool age, and another that
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commences in late childhood (Polier, Vloet, & Herpertz-Dahhmann, 2012). Moffitt,
Caspi, Harrington, and Milne (2002) followed 1037 children from the age of three to 18,
with a follow-up study of the cohort at age 26, and a second follow-up study by Odgers et
al. (2007) of the same cohort at age 32. Odgers et al. reported those children who were
diagnosed with ADHD early in childhood (pre-school aged), and who also exhibited
persistent antisocial behaviors throughout childhood and into adulthood, were often
involved in violent behaviors and had more health and financial issues. Even though this
subset of the cohort represented only about 100 children (10%), they also accounted for
roughly 70% of the time participants spent incarcerated. Klein et al. (2012) also reported
youth with ADHD (36%) had a significantly greater incarceration rate as compared to
those without ADHD (12%), which supports the adverse impact and deleterious effects of
ADHD.
According to Burt, Obradovic, Long and Masten (2008), maladaptive behaviors in
adulthood can be predicted by diminished social behavior in childhood. Mrug, Hoza, and
Gerdes (2001) assert hyperactive children with ADHD typically benefit from a
combination behavior management training and medication. Thus, treatment
effectiveness may be decreased when medication is discontinued or children are
nonadherent.
Substance use disorder and other risky behaviors. Researchers reported the
likelihood of developing substance use disorder (SUD) is increased for those diagnosed
with ADHD. Wilens et al. (2011) reported there is a considerable increase in risk for
SUD in children diagnosed with ADHD, however, conduct disorder, which often co-
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occurs with ADHD, alone has been shown to be a risk factor for SUD, including tobacco
smoking, This is important is important as Brook, Brook, Zhang, and Koppel (2010)
reported SUD in youth with ADHD may be mediated by conduct disorder.
ADHD in children has been implicated in the display of risky behaviors such as
risky sexual activity and risky driving. Flory et al. (2006) found youth with ADHD
initiated earlier sexual activity, had an increased numbers of sexual partners, had more
casual sex, and a greater number of pregnancies. The researchers contend poor social
functioning can steer youth toward affiliations with peer outcasts and outsiders who are
more likely to participate in deviant behaviors. Family conflict, as a result of the
negative behaviors demonstrated by some children with ADHD may also be a
contributor.
Quality of life. Quality of life, which includes a person’s perception of their
psychological, physical, and social performance, can be improved by medication. Most
studies that assessed quality of life and medication were those conducted with the nonstimulant medication Atomoxetine. In a systematic review of literature by Danckaerts et
al. (2010), one study found medication resulting in a significant improvement in family
engagement, behavioral health scores and psychosocial scores compared to placebo.
Another study reported a significant increase in symptom ratings from teachers and
parents after children took Atomoxetine. Two studies that utilized amphetamine salts
were reviewed and both studies revealed statistically significant increases in quality of
life scores at endpoint. These studies demonstrate that medication can positively impact

38

how children perceive their quality of life, which is a direct impact of mental, physical
and social well-being.
Treatment
Medication. Medication is the most commonly used treatment for ADHD and can
vary based on gender and geography. In 2012, the southern United States, specifically
South Carolina, had the highest reported use of ADHD medication (5%), and for
adolescent boys between the ages of 12 and 18, medication use was as over 14% (Express
Scripts, 2014). These rates are 72% higher than those reported for the national average,
and there is speculation that appropriate ADHD diagnosis, school-related testing that
penalizes teachers for poor student performance, the lack of resources in the school
system to address behavioral issues, and lower SES, are contributors to this inflated rate
of medication utilization (Express Scripts, 2014). This data reflects geographic
differences in medication use across the United States.
The two types of medications most frequently utilized are categorized as
psychostimulants (e.g. amphetamine derivatives, methylphenidate) and norepinephrine
reuptake inhibitors (Charach et al., 2011). While both have had some success in the
treatment of ADHD symptoms, stimulants are the most frequently used medications and
are first-line treatment for ADHD (Weyandt et al., 2014; Zuvekas & Vitiello, 2012).
Evidence indicates non-stimulant medications are also safe and effective at relieving
ADHD symptoms (Busche & Savill, 2014). They are particularly effective for those who
fail to respond to stimulants and who also have comorbid substance use disorder
(Weyandt et al.). These individuals have a higher abuse potential to stimulant
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medications due to their affinity for the dopaminergic system, whereas non-stimulants
target the norepinephrine neurotransmitter system (Weyandt et al., 2014). However,
researchers have also reported patients who take non-stimulants are less adherent and
have decreased medication persistence as compared to those who take stimulant
medications (Christensen, Sasane, Hodgkins, Harley, & Tetali, 2010). This may be
attributed to medication efficacy, which is one of the most commonly reported reasons
for the discontinuance of ADHD medication.
Feldman and Reiff (2014) reported long-acting and sustained release stimulants
have a greater preference over short-acting stimulant medications due to once a day
morning dosing. This dosing schedule provides effective control of symptoms
throughout the school day with limited side effects (Feldman & Reiff, 2014). The longterm use of stimulants and their cardiovascular safety profile trepidation among patients
and practitioners. However, Cooper et al. (2011) found there is no increased frequency
of unexpected death in children who utilized stimulants than what is found in the general
population. Although these findings indicate there is no increased risk, in 2008 the
American Heart Association recommended that practitioners conduct an
electrocardiography prior to the initiation of treatment with stimulants (Feldman & Reiff,
2014).
Atomoxetine, a selective norepinephrine reuptake inhibitor, is the most well
known non-stimulant medication (Polier et al., 2012). The investigators reported that
although it may take a few weeks before the complete benefit of the drug is realized, the
drug has been implicated with significant improvements in ADHD symptom severity.
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Newcorn, Spencer, Biederman, Milton, and Michelson (2005) reported Atomoxetine has
also been effective in mitigating aggression related to impulsivity in those with both
ADHD and oppositional defiant disorder. Although some literature supports the
effectiveness of Atomoxetine, stimulants are recommended as first line therapy, with
short-acting stimulants demonstrating fewer side effects, which can lead to better
adherence.
Behavior therapy/counseling. Behavior therapy has been utilized alone and in
combination with medication to change behavior. Cognitive Behavior Therapy (CBT),
which is used in both children and adults, has been recommended for children 5 and
under, in combination with pharmacotherapy, and for children unable to tolerate
psychostimulants (The American Academy of Pediatrics, 2011). Antshel, Farone, and
Gordon (2014) reported that although there is some literature that indicates CBT is an
effective treatment option for children and adolescents, CBT has demonstrated stronger
efficacy in adolescents (Baer & Nietzel, 1991) and in adults (Safren et al., 2010) versus
children, and suggested CBT efficacy may be moderated by cognitive development.
While some children may have a singular diagnosis of ADHD, it often presents with cooccurring psychopathology, such as anxiety, mood disorders, and disruptive behavior
(Kessler et al., 2006). Antshel et al. (2014) found adolescents with multiple mental
health disorders (e.g. conduct disorder, and oppositional defiant disorder) received less
benefit from CBT than those with ADHD alone or ADHD and anxiety or depression.
The researchers further reported although adolescents with ADHD alone and ADHD and
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anxiety or depression did realize some gains in functioning, they remained symptomatic
and continued to experience some functional impairment.
Bussing et al. (2012) found negative attitudes were correlated with behavior
therapy and counseling. Participants reported psychotherapy and counseling were
generally ineffective, particularly when used alone. In addition to the cost associated
with counseling, participants expressed concern around the stigma tied to the receipt of
counseling and the possibility that public awareness of their counseling would have a
devastating impact. Behavior therapy consistency for the family and across the
continuum of care was reported as the greatest burden of this treatment option (Bussing et
al., 2012). Parents can be trained on how to utilize interventions, such as positive and
negative reinforcement, which can result in successful behavior modification and help
their child to self-manage their behavior (American Academy of Pediatrics, AAP, 2011).
Another behavioral intervention that has been utilized is behavior classroom
management, which is designed to increase classroom rules compliance and productivity,
and minimize disruptive behavior (AAP, 2011). While behavior management is the firstline recommendation for younger children (ages 4-5), it may not be enough to sufficiently
reduce problematic ADHD behavior, thus the addition of medication may be required,
per AAP treatment guidelines (AAP, 2011). Although some children, parents, and
teachers may find this treatment useful, it does not appear to be the most efficacious.
ADHD Treatment Guidelines
The American Academy of Pediatrics (2011) has provided guidelines for the
treatment of ADHD and recommends the following:
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1. Children between 4 and 5 years of age: In areas where behavioral treatments
are available, they are recommended first-line. If the intervention does not
provide a significant improvement and behavioral disturbances persist,
methylphenidate may be prescribed, however the potential harm versus the
benefits of starting medication at an early age should be weighed.
2. Children between 6 and 11 years of age: U. S. Food and Drug Administration
approved ADHD medication and/or parent/teacher provided behavior therapy
is recommended first line, with a preference for a combination of the two.
The AAP reports there is strong evidence in support of the use of stimulants,
and further recommends school involvement as part of the treatment regimen.
3. For children between 12 and 18 years of age: U. S. Food and Drug
Administration approved ADHD medication is recommended with adolescent
assent. Medication should be used preferably in combination with prescribed
behavior therapy.
Medication Adherence
Medication adherence is defined as the degree to which a person’s behavior
matches the agreed recommendations from a health care practitioner, including following
diet and lifestyle changes as well as taking medication (World Health Organization,
2003). Medication may provide children and adolescents with ADHD with a significant
opportunity to achieve long-term treatment success if they adhere to the treatment
regimen (Chacko et al., 2010). Reasons attributed to medication adherence (which is
only around 50%) are patient-related (e.g. SES; Brown & Bussell, 2011), medication-
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related (e.g., efficacy; Barner, Khoza, & Oladapo, 2011), and environment-related (e.g.,
parental beliefs; Ferrin & Taylor, 2011, Garbe et al., 2012; Zetterqvist et al., 2013).
Dawood et al. (2010) contend that for children with chronic illness, the lack of parental
understanding of their child’s illness, reticence around therapy efficacy, and concern
about adverse effects of medication, impact children’s adherence. Thus, parents have the
largest impact on their child’s medication initiation and adherence (Bai, et al., 2015).
Medication interventions have demonstrated proven success in mitigating the
ADHD symptoms of hyperactivity, inattention, and impulsivity, which contribute to
social and academic impairment as well as risky behaviors. Specifically, medication has
been shown to increase academic performance (Connor, 2005), improve mathematic
scores (Molina et al., 2009), and enhance cognitive performance (Bedard, Jain, Johnson,
& Tannack, 2007; Swanson, Baler, & Volkow, 2011). In a systematic review of
literature by Shaw et al. (2012) to compare the long-term impact of ADHD treatment vs.
non-treatment, several studies that looked at the long-term impact of no ADHD treatment
over a period of nine years. Four studies indicated participants deteriorated significantly
from baseline measures. For example, in one study, Powers, Marks, Miller, Newcorn,
and Halperin (2008), investigators found children who had never or who had received
minimal pharmacologic treatment for ADHD scored significantly worse on standardized
academic achievement tests than those who had no ADHD diagnosis.
In another group of studies from the Shaw et al. (2012) literature review, driving,
obesity, self-esteem, social function, academics, drugs, antisocial behavior, the use of
services, and occupation were utilized as outcome endpoints for medication treatment for
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ADHD. Medication treatment achieved the greatest benefit on driving, obesity, selfesteem, and social and academic function. However, improvements in obesity is may be
attributed to the side effects of amphetamines, which is appetite suppression. Shaw et al.
noted that although many studies reported an improvement in the outcome measures for
those treated with medication, medication is unable to normalize or to eliminate
completely the symptoms and adverse behaviors associated with ADHD. Therefore,
when individuals who have received treatment for ADHD are compared to those without
ADHD, those without ADHD still tend to perform better.
Attempts to increase medication adherence include enhancing parental knowledge
and information regarding ADHD, educating parents on the safety of medication and the
social acceptability of medication, behavior therapy, and psychoeducation (Bussing et al.,
2012). However, Wang, Maursky-Horowitz, and Chronis-Tuscano (2015) reported
parents own experience with ADHD could impact their child’s treatment outcome. The
researcher asserted this is due primarily to the manifestation of the parent’s own ADHD
symptoms, leading to poor and/or inconsistent monitoring and adherence to their child’s
pharmacologic treatment regimen, ultimately producing inadequate pharmacological
response. Wang et al. reported that interventions designed to help parents attain better
control of their own ADHD symptoms may create a trickle-down effect that leads to
better medication adherence for their children. However, it is not clear as to the degree to
which parental ADHD and the control of parental ADHD symptoms actually impact
children’s medication adherence.
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Demonceau et al. (2013) conducted a systematic literature review and metaanalysis to assess interventions utilized to increase medication adherence. Eight types of
interventions were evaluated including (a) treatment simplification (changing dose
schedule and/or medication formulation, (b) cognitive-educational (education in group
settings), (c) behavioral counseling, (d) social-psycho-affective (social support and
relationships, (e) electronically monitored adherence feedback or EM-feedback
(electronic feedback on patient dosing history), (f) technical reminder systems (i.e.
mobile text messages), and (g) rewards. The researchers found patients who received
EM-feedback had the greatest improvement (7.7%), and rewards were second. However,
variations in study sample size, the repetition of the intervention, method for
randomization, and the way adherence was operationally defined in studies may have
impacted the study results (Demonceau et al. (2013).
Researchers revealed that while some interventions (psychoeducation and
behavior therapy) may have some incremental impact on increased medication adherence
in the short term (Dean et al., 2010; Hebert et al., 2013), an intervention that substantially
increases medication adherence remains a challenge (Sitholey et al., 2011). Methods to
reduce the economic loss, social impairment, and poor clinical outcomes related to poor
ADHD medication adherence remains of significant importance to healthcare
professionals and researchers (Bussing et al., 2012; Lehmann et al., 2014; Schwebel et
al., 2011).
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Patient–Related Factors
In this research, the patient is defined as the “parent-child dyad” because for
children between the ages of 5 and 12, the parent(s) is the one generally responsible for
medication administration (Chacko et al., 2010). As children age and become
adolescents, they tend to be more vocal about their opinions related to ADHD medication
and whether they will adhere and persist with their medication. The patient chiefly
determines medication adherence, although many factors can influence whether the
patient decides to initiate, adhere, and persist with treatment. Brown and Bussell (2011)
argued the involvement of patients in their care is a key contributor to improved patient
associated medication adherence.
Age. Age has been examined extensively as a factor that contributes to
medication adherence. As children age, they become more vocal in their desire to be
adherent to medication and parents wield less influence on their children’s medicationtaking behavior. In a qualitative study by Avisar and Lavie-Ajayi (2014), six of 14
participants completely discontinued medication after elementary school. Selective
adherence was reported by three of the 14 participants, and only five participants reported
that they persisted with their medication. However, they were also the younger
participants in the sample. All of the participants reported they either completely stopped
taking their medication or only took it intermittently by the time they reached high
school. Of significance is that only one participant was advised by his parent to stop
taking the medication due to a lack of improvement and the presence of side effects.

47

Although age has been cited as a factor that impacts medication adherence, some
researchers dispute the role age plays in adherence. Hebert et al. (2013) contend
medication adherence was not significantly impacted by a child’s age. They found there
were two factors that positively predicted adherence: 1) child’s gender (male), and 2) the
parent’s perception of the psychosocial benefits of medication after three months.
The researchers further reported parent’s perceived psychosocial benefits of medication
can be increased through their medication acceptability and through clinician-driven
medication education, targeted toward the child, regarding the benefits of medication on
psychosocial skills
Socioeconomic status. Patient SES status is a significant factor that can adversely
impact medication adherence (Brown & Bussell, 2011). Low SES directly affects a
patient’s access to healthcare including transportation to appointments and the pharmacy,
as well as their ability to pay for medication and services. Children who live in
neighborhoods with limited access to a pediatrician and/or low-income areas may have
worse health habits than those with higher SES (August & Billimek, 2015). Even if the
child has health insurance, access to preferred medication that may have fewer side
effects or be more efficacious could be a barrier to treatment adherence. Patients may
also skip doses or not take the prescribed amount of medication due to the cost of
medication costs. Billimek and August (2014) reported that medication cost is a core
contributor to intentional nonadherence. When the researchers assessed the role of costs
and beliefs about medication of Mexican Americans who had type 2 diabetes, they found
participant beliefs was the greatest contributor to adherence. Billimek and August
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reported participants beliefs were associated with neighborhood deprivation, but income
or the type of insurance, and the opposite was true of medication cost, where cost was
related to type of insurance and income.
Bussing et al. (2003) evaluated the influence of social networks and found there
were significant differences in in network characteristics based on SES and ethnicity.
Those networks which comprised White parents with higher SES were larger and
included more healthcare practitioners. Even these results suggested White parents had
greater access to healthcare professionals and increased opportunity to seek their advice.
African American parents leaned more heavily on an informal network, consisting of
family and friends and reported they had adequate social support.
Medication-Related Factors
The most commonly reported ADHD medication-related factors attributed to nonadherence are side effects and poor efficacy. Medication side effects include changes in
mood, depression, irritability, suppression of appetite, and insomnia (Singh et al., 2010;
Toomey et al., 2012). Toomey et al. (2012) surveyed parents of children with ADHD
and found 21% of children no longer persisted with medication, and 42% of those
discontinued within the first 30 days of medication initiation. An additional 33%
discontinued between 4 and 6 months of initiation and 4% persisted for more than 6
months. The researchers reported 34% was attributed to poor medication efficacy and
62% of medication discontinuance was attributed to medication adverse effects.
Additionally, up to 71% of children reported they experienced side effects.
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Sitholey et al. (2011) assessed 24 newly diagnosed adolescents and children with
ADHD from India to determine the factors related to medication adherence. The
researchers found participant nonadherence exceeded 83% in the first month. Medication
side effects were reported by 65% of participants, and poor medication efficacy was
reported by 50% of participants. While the study results were congruent with other study
reports on reasons for medication nonadherence, the small sample size impedes the
generalization of the results.
Several researchers have also cited medication side effects and poor efficacy as
the primary reason for medication nonadherence (Cutler & Everett 2010; Laba et al.,
2015). However, in a qualitative study to assess young people’s experiences of stimulant
medication and ADHD, several youth reported their medication had a positive effect on
their social behavior, increased their focus and concentration in the classroom, and
improved their school work (Singh et al., 2010). While several participants reported they
experienced school work improvement, the benefits of enhanced focus and concentration
were not completely alleviated and participants still reported they experienced significant
difficulty with school work. However, most of the youth expressed positive medication
experiences and indicated they needed their medication. They further related improved
social behaviors of the medication with improved peer relationships.
Environmental-Related Factors
Parental beliefs. Parental attitudes, beliefs, and perceptions are paramount to
medication adherence (Ferrin et al., 2012). Toomey et al. (2012) examined why children
discontinue their medication and asked parents to rate a series of questions related to
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ADHD and medication. The researchers found medication discontinuation was
correlated with positive parent agreement with the following statements: (a) “I prefer
counseling over medicine to treat my child”; (b) “I feel that medicines to treat ADHD had
bad side effects”; (c) “ADHD is best treated with counseling”; (d) “Sometimes [my child]
doesn’t need to use as much ADHD medicine as the doctor prescribed”; and (e) “I worry
about the long-term effects of ADHD medicines” (p. 766). Therefore, parental
perceptions and beliefs were correlated with parental behavior and medication adherence.
Hamrin et al. (2010) suggested that parent and child ambivalence toward
medication is created through cultural messages that facilitate fear. Some messages, both
cultural and not, influenced medication-taking behavior around disease and medicationrelated stigma. Hamrin et al. reported researchers found 45% of stigma was related to
childhood mental health treatment that resulted in rejection in the school setting. In
response to questions around mental health issues and the treatment of children with
medication, participants reported (a) physicians prescribed too much medication; (b)
long-term developmental side effects are caused by medication; and (c) medication
postponed addressing the actual child’s issues (Pescosolido, Perry, Martin, McLeod, &
Jensen, 2007). This research supports the contention that attitudes and beliefs impact
parental behavior related to medication.
Ferrin and Taylor (2011) contended illness management is directly impacted by
the core beliefs of the patient, and suggested the treatment outcome for children and
adolescents are most likely influenced by their attitudes. Johnston, Seipp, Hommersen,
Hoza, and Fine (2008) reported parents who believed ADHD was attributed to
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environmental or psychological influences versus biological causes had a greater
propensity to encourage medication adherence for their children. They reported safety
and efficacy of medication to moderate ADHD symptoms also greatly impacted parental
medication adherence.
In a Danish study of 62,304 children, adolescents and adults up to 49 years of age
to determine second prescription refills of ADHD medication, only 7,441 (12.6%) refilled
their prescription a second time (Pottegård, Bjerregaard, Kortegaard, & Zoega, 2015).
This number represents a decrease in second prescription refills over time. Similar
results were found regardless of the gender, type of drug taken (methylphenidate
immediate release, methylphenidate extended release, or atomoxetine), or age.
However, adults discontinued medication over time at a greater rate than children and
adolescents. Pottegård et al. suggested this may be attributed parental involvement in
their child’s medication taking, since parents are generally the decision-maker regarding
medication persistence.
Raman et al. (2015) evaluated children aged 3 to 16, who were prescribed ADHD
medication in the primary care setting in the United Kingdom between 1994 and 2006.
The researchers looked at both the duration of the initial treatment course and the span of
time between the courses of treatment. Initial treatment course duration lasted from the
date the first medication was prescribed through the end of the last ADHD prescription
medication treatment period. Treatment periods included a grace period of 30-days in for
the main analysis and 60 and 90 grace periods for secondary analysis. Children who
continued with their first course of treatment for more than six months were considered
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persistent, and those who continued for less than 6 months were considered nonpersistent.
The treatment gaps between treatment courses for those children who had multiple
treatment courses were also determined. Raman et al. found just 35% of children were
persistent with their medication at six months following their initial prescription, even
with a 30-day grace period. And when given a 60-day grace period, only 57% of children
were persistent. Long-acting methylphenidate was also associated with medication
persistence at the six-month mark. The investigators supported Charach and Fernandez’
(2013) assertion that elements not typically measured or collected in databases, such as
attitudes around medication may be influenced by family and/or youth attitudes.
Nagae, Nakane, Honda, Ozawa, and Hanada (2015) assessed parental adherence
and the factors that impact medication adherence in children who obtain outpatient
medication. They evaluated 30 pairs of mothers and children who ranged in age between
7 and 17. The investigators found when mothers acknowledged their child’s symptoms
had improved following psychiatric visits and when mothers recognized symptom
improvement was attributed to the effects of the medication, medication adherence was
impacted. However, contrary to other research, no correlation was found between
medication adherence and child age.
Parental Experience With ADHD
Parents who at some point were diagnosed with ADHD and prescribed
medication for treatment are influenced by their experiences with treatment. Parents’
experiences with psychotropic medication are correlated with their willingness to
consider psychotropic medication for their child’s mental illness (Hamrin et al., 2010).
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For parents who have experienced a mood disorder and who have also had good and
successful experiences with psychiatric medication associate their positive experience
with the acceptability of the same type of treatment for their child (Chavira, Stein, Bailey,
& Stein, 2003). In a study of 156 parents who had previous experiences with
psychotropic medication, most attested to strong support for short and long-term
treatment with medication (Post, Leverich, Fergus, Miller, & Luckenbaugh, 2002).
Hamrin et al. (2010) asserts previous parental experience with psychotropic medication
allows for the opportunity to more accurately establish expectations and to measure the
cost and benefits of the medication for their children. However, some researchers
contend for those parents where ADHD has persisted into adulthood, the familial history
of ADHD is correlated with lower medication adherence, which may be due to their
inadequate management and monitoring ability related to ADHD (Gau et al.,2008).
Medication Education/Psychoeducation
The benefits and accuracy of information related to medication is essential to
psychotropic medication acceptance. Berger, Dor, Nevo and Goldzweig (2008) found
most parents of children with ADHD had received negative information in regards to
methylphenidate, which led to adverse attitudes about the medication. However, over
90% of parents and children reported the greatest influence related to their acceptance of
methylphenidate was the medication education provided by the neurologist. These
findings support the theory that affirmative parental beliefs associated with prescribed
medication can create a significant impact on medication taking behavior and adherence.
Berger et al found that medication education was advantageous during the medication
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initiation phase. However, Johnston, Hommersen, and Seipp (2008) found it did not
contribute to medication persistence. Corkum et al. (1999) also supported this assertion
and reported adherence to stimulant medication over one year did not experience the
same impact that parental ADHD knowledge had on medication initiation.
Bussing et al. (2012) conducted a longitudinal mixed methods study that included
students, parents of elementary school students, and teachers. The investigators found
teacher-reported behavior ratings for both students with and without ADHD, indicated
that some general negative perceptions were correlated with ADHD education.
Participants also reported while education is an important initial step, it must be
combined with a plan and/or strategies to be effective. A strong and supportive social
network that involves the family, school, and healthcare providers responsible for the
child’s care are important for the achievement of medication adherence success (Dawood
et al., 2010).
Patient-Centered Medical Homes
Definition and Recognition of PCMHs
The concept of PCMHs originated through the Academy of Pediatrics in 1967 and
was designed to help with the care of children with special health care needs (CSHCN;
Sia et al., 2004). The term medical homes are also used interchangeably with PCMHs in
the literature. It is estimated that children with special health care needs account for
almost 20% of the pediatric population and encompass approximately 80% of pediatric
health care spending (Hamilton et al., 2013). Following the adoption of the Patient
Protection and Affordable Care Act in 2010, which included the requirement to establish
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PCMHs, medical homes have been widely adopted across the United States (Fields, et al.,
2010). The Patient-Centered Primary Care Collaborative (PCPCC 2013) defined
PCMHsas a model of primary care or health delivery that takes on a team approach with
a focus on care excellence. According to PCPCC, primary care or pediatric providers can
be designated as a PCMH if they meet all five components of the following criteria:
1. Patient-Centered: Patients and families are provided with support to manage
and to participate in their care as informed partners.
2. Comprehensive: The health care team is fully accountable for all of the
patient’s physical health and mental health needs.
3. Coordinated: Health care is coordinated throughout the health system to
facilitate transition between specialty providers, hospitals, home health, and
community and public health.
4. Accessible: Provides 24/7 access, via electronic or phone, offers decreased
wait times and extended hours, and communication facilitated through health
information technology.
5. Committed to quality and safety: Quality improvement is demonstrated
through information technology innovation and tools that assist families with
informed decision-making.
It is hypothesized that through these components that (a) patients will not
postpone or avoid needed medical attention; (b) there is less medical and procedure
duplication; (c) there is better chronic disease management which leads to improved
outcomes; (d) there is a reduction in chronic disease severity; and e) there are cost

56

savings such as fewer emergency room visits and accurate medication utilization
(Patient-Centered Primary Care Collaborative, 2013). These provisions may also impact
the effectiveness of PCMHs through the enablement of patient engagement and increased
disease state comprehension and treatment support.
The NCQA reports as many as 10% of primary care practices in the United States
are recognized as a PCMH (NCQA, 2014). The NCQA is the first organization to offer a
program to recognize PCMHs. However, The Joint Commission now offers a PCMH
certification. With increased support, more organizations continue to seek PCMH status.
This is evidenced by (a) the Department of Defense’s intention to convert all of their
primary care practices to NCQA recognized PCMHS (NCQA, 2014), (b) the Department
of Health and Human Services plan to help practices become PCMHs, and (c) Medicare’s
plan to provide reimbursement to providers who deliver chronic care through non face-toface means.
Benefits of Patient-Centered Medical Homes
Literature around PCMHs and CSHCN indicated medical homes are beneficial to
the treatment and care of this population. Researchers found 58% of the parents
experienced a significant health care burden while caring for their child with special
health care needs, but only 53% of CSHCN acquired care in a medical home (DuPaul,
Carson, & Fu, 2013). When patients did receive care in a medical home the receipt of
patient-centered care, assistance coordinating care, and assistance with referrals had the
greatest impact on the reduction of time burden for caring for CSHCN (Miller, Nugent, &
Russell, 2013). Parents who had a medical home experienced between a 15-22%
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reduction in the amount of time spent arranging or coordinating care, and a 16-19%
reduction in the odds related to the burden of providing home care for the child.
However, if even one of the five components of a medical home was absent, there was a
reduction in the effectiveness of the home for families of CSHCN (Miller et al. 2013).
This research may have a significant impact on parents seeking medical care for their
child with ADHD and how their treatment can be more effectively managed.
Boudreau et al. (2014) reported coordinated care is a vital medical home
component and found children who received coordinated care, in general, had fewer
unmet specialty health care needs. Additionally, children who received coordinated care
within a medical home, experienced a one third decrease in unmet specialty care needs
(Boudreau, et al., 2014). These results demonstrate specialty care, which encompasses
mental health diagnosis and treatment related to ADHD, may be more sufficiently
addressed in a medical home and lead to increased medication adherence as well as fewer
unmet needs of parents and children with ADHD.
In a study of over 5,000 children, Knapp et al. (2012) examined the factors related
to having a medical home and the impact of the medical home on outcomes. Knapp et al.
(2012) reported those children who are socioeconomically disadvantaged and/or are
ethnically diverse are less likely to utilize a PCMH and are more apt to have unmet
needs. The researchers reported this was largely due to the lack of insurance, caregiver
strain, and paternal survey participants more likely to report they did not have a PCMH.
Miller, Nugent, Gaboda, and Russell (2013) also supported these findings and reported
children without a medical home are up to three times as likely to report an unmet need.
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Hamilton, Lerner, Presson, and Klitzner, (2013) suggested PCMHs create positive
experiences for socioeconomically disadvantaged parents of ethnically diverse children
with complex healthcare needs. This is seen more specifically in the area of care
coordination. The findings of Knapp et al and Miller et al. demonstrated that
unfortunately, a significant number of children in this population are not receiving these
important benefits.
Family-based care and medication decision-making are key benefits of the PCMH
(PCPCC, 2012). This type of care may help families to provide significant influence
over adolescent medication taking behaviors and increase their teenager’s investment in
the treatment regimen (Hogue, Bobek, Tau, & Levin, 2014; Stille et al., 2010). Hogue et
al. asserted interventions that provide a focus on family, provide an avenue for parent and
family behavior monitoring and ultimately influence medication decision-making. A
core feature of PCMHs is a focus on patient support and involvement in their own care.
Patients are encouraged to actively participate in the development of their care plans and
acknowledgement of patient culture and attitudes are woven into the treatment regimen.
This patient-centered component is in line with the literature that has demonstrated
increased patient adherence rates are related to patient involvement and may be a critical
PCMH component that contributes to patient adherence to medication.
The improvement of health outcomes is a central goal for PCMHs (Adamson,
2011). In a survey conducted by Raphael et al. (2015) of children enrolled in Texas
Children’s Health Plan, which is a managed care health plan serving low-income
children, parents of children with chronic conditions reported fewer emergency
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department visits and hospitalizations if they had a PCMH. PCMH communication and
staff education were the crucial factors reported to be associated with this reduction in
resource utilization. A reduction in ED visits and hospitalizations reduce overall
healthcare costs and the burden of treating chronic diseases like ADHD. Nielsen, Buelt,
Patel, and Nichols (2016) reported PCMHs provide (a) care plans that are personalized to
the patient, provide medication review to help patients better understand and manage
medication, (b) offer advice and coaching to assist patients with health goal attainment,
and (c) help patients to connect with peers and those in the community with similar
health experiences; who provide patient encouragement. These benefits may improve
medication adherence for children with ADHD and reduce healthcare spending and
resource utilization associated with adverse ADHD behaviors (Cutler & Everett, 2010;
Hamilton et al., 2013; McGrady & Hommel, 2013; Toomey et al., 2011), as PCMHs
have been shown to reduce utilization of healthcare services and are associated with
improved health outcomes (Toomey et al. 2011).
Medical Home Attainment
Knapp et al. (2012) also found that White children are almost twice as likely to
have a PCMH as ethnically diverse children, and children who had a physical or mental
diagnosis in addition to ADHD, were up to 63% more likely not to have a medical home
versus children with ADHD alone. Knapp et al. (2013) agreed with these findings and
found for children with multiple behavioral health diagnoses, the likelihood of having a
medical home was decreased. These finding suggest PCMH attainment is significantly
impacted by SES, ethnicity, physical and mental comorbidities which are common for
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children with ADHD. Richmond and Berry (2012) assert a person’s perceptions and
experiences regarding health care are significantly influenced by culture. Therefore, the
introduction of these children to the benefits of PCMHs may decrease healthcare
disparities and potentially reduce suboptimal healthcare experiences.
Adams, Newacheck, Park, Brindis, and Irwin (2013) reported that over the past 12
months, more than half of adolescents had a medical home. Children who resided in
homes that were non-English speaking and lower income, who were uninsured, and who
were minorities, were also less likely to have a medical home. Adams et al., suggested
disparities in healthcare can be decreased for youth with lower SES and/or complex
medical needs through the application of PCMH components, such as care coordination
and family-centered care.
While the majority of research indicates medical homes do improve health
outcomes and increase the level of coordinated care for patients, there continue to be
some impediments to the full implementation of the PCMH model. Richmond and Berry
(2012) reported ethnic/racial disparities related to transition services persist within
medical homes, between White and Non-Hispanic Black children with special health care
needs. In their research, transition services referred to the five components that define
the medical home. The investigators reported roughly only 57% of CSHCN received all
of the services that are available through the PCMH components. This percentage is
critical, as more than 11 million, or over 15% if children in the U.S. have special health
care needs (U. S. Department of Health and Human Services, 2013). This represents a
disappointing percentage of CSHCN are achieving full PCMH benefit. These findings
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indicate there is a lot of room to improve PCMH efficacy and compliance with program
equality.
The Maternal and Child Health Bureau (USDHHS; MCHB, 2013) has identified
the outcomes that are essential to evaluating CSHCN needs, which enable the
measurement of the national progress of the PCMH components. As of 2013, only 43%
of CSHCN met the standard for receipt of coordinated and comprehensive care in a
medical home. The measures indicated almost all CSHCN had a personal doctor or
nurse, 75% had a place they usually go when they are sick, 65% received family-centered
care, and 23% encountered problems in the attainment of referrals (USDHHS; MCHB,
2013). These less than ideal results also demonstrate a significant opportunity for
improvement in medical home operations and service delivery.
The greatest predictor of these reported disparities was the availability of
adequate insurance and how services are reimbursed. Because many of the benefits and
services delivered in a PCMH are not always reimbursed, such as (a) referral to
specialists, (b) assistance with medication management, and (c) time spent to develop
patient/provider relationship (Antonelli & Antonelli, 2004; Bodenheimer, 2006;
McAllister, Sherrieb, & Cooley, 2009), providers offset the lost revenue by limiting the
number of non-reimbursable PCMH services they provide to CSHCN (White, 2002).
This current reimbursement structure continues to support a fragmented system of
healthcare delivery. However, the Centers for Medicare and Medicaid will soon offer a
PCMH definition and certification to allow for incentive payments, which should
encourage PCMH compliance with service delivery standards (PCPCC, 2016). This
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revision in Centers for Medicaid and Medicare Services policy should help to alleviate
poor practitioner reimbursement as a barrier to the full implementation of PCMH services
(PCPCC, 2016).
MCHB reported insurance benefits and provider access for CSHCN was
frequently reported as a barrier to the receipt of PCMH components, as opposed to actual
insurance coverage. MCHB also reported CSHCN have a greater potential to have
insurance than the population of children in general, with as few as 3.6% of CSHCN
reporting they did not have insurance (USDHHS, 2013), and just over 9% reporting that
at some point within the last 12 months, they lacked insurance. Over 33% of participants
reported their insurance was not always sufficient to meet their child’s needs, due to
insurance benefit design, out of pocket costs, or lack of provider access, which represents
the larger issue for CSHCN and PCMH service attainment. Therefore, while 90% of
CSHCN have uninterrupted health insurance, only 60% met all of the standards for this
core outcome.
Patient-Centered Medical Homes Measurement
Rosenthal, Abrams, and Bitton (2012) reported that while PCMHs have been
recognized as a promising answer to reduce the level of fragmented care that currently
exists in the healthcare system, population inconsistencies and variable focus on PCMHs
based on geography make it difficult to generalize quality measures. In an effort to
address this issue, a core set of cost and utilization measures were developed in 2009 by
the Patient-Centered Medical Home Evaluators’ Collaborative. A recommended core
measurement of pediatric quality for evaluation of PCMHs includes follow-up care for
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children who have been prescribed ADHD medication. This measure is designed to
quantify the effectiveness of behavioral health care and to evaluate the percentage of
children who have been newly prescribed ADHD medication and have had at least three
follow-up visits within 10 months (Rosenthal, Abrams, & Bitton, 2012). One of the three
visits must have occurred within the 30 days of when the initial ADHD medication was
dispensed (Rosenthal et al., 2012). Grabowski (2012) also supports the use of medication
adherence as an effective performance measure of PCMHs, as medication adherence is a
significant determinant of treatment outcomes (Dean et al., 2010).
Additional issues with the accurate measurement of PCMHs include the variation
in the individual components of PCMHs and the way the components may work in
combination to impact PCMH effectiveness (Alexander & Bae, 2012). It is important to
keep in mind that research that finds PCMHs lack effectiveness in their ability to improve
outcomes may have more to do with poor execution of PCMH components and less to do
with the PCMH model itself (Alexander & Bae, 2012). For example, some PCMHs may
spend more time developing the patient/provider relationship, which can have an effect
on patient trust in the provider, and positively influence patient adherence. However, this
research will not examine component execution, but it may be an area for future research.
PCMH success and improved health outcomes are already being realized in the
state of Missouri. Care Management Technologies (2016) reported Missouri is the first
to take advantage of the federal incentives earmarked for states to implement medical
homes. Their data analytics tool, which is in line with the information technology core
component for PCMH designation, has been an integral part in helping the state Medicaid

64

agency, MO HealthNet, to track claims data, manage individualized care goals, identify
at-risk patients, implement targeted care management interventions, and monitor patient
progress with those goals. During the first year of implementation, the state saved $31
million dollars, which were largely attributed to hospitalizations, unnecessary emergency
room visits, and care for enrollees with chronic mental and physical health disorders.
(Care Management Technologies, 2016). The tremendous success of the medical home
program in Missouri demonstrates the significant impact program implementation can
have not only on state finances, but also more importantly on patient health outcomes.
Summary and Conclusions
The review of the literature revealed ADHD is a chronic mental disorder that
affects a significant number of children in the United States with treatment costs in the
billions (Cutler & Everett, 2010). The exact reason for ADHD development is unclear,
however, there is convincing evidence that genetics play a central role in ADHD etiology
(Banaschewski et al., 2010). Non-adherence to ADHD medication is reported to be as
high as 87% (Ahmed & Aslani, 2013), and researchers reported some of the greatest
contributors to non-adherence include parental beliefs, medication side effects,
medication efficacy (Toomey et al. 2012), patient age (Avisar & Lavie-Ajayi, 2014), and
SES (Brown & Bussell, 2011). Uncontrolled symptoms of ADHD (inattention,
hyperactivity, anxiety, and aggression) can lead to social and academic impairment, risky
behavior, and diminished quality of life (Danckaerts et al., 2010; McConaughy et al.,
2011; and Robb et al., 2011). McClain and Burks (2015) reported treatment received in a
family-centered care setting may increase the medication-taking behavior of youth, and

65

suggested that the increased engagement in treatment could impact their opinions
regarding the value of treatment and increase ADHD symptom management. Litzenburg
(2014) also suggested that an increase in shared decision-making between medical
personnel and caregivers could result in improved ADHD medication adherence. This
literature supports the use of PCMHs, which utilize a shared approach and increase
patient treatment engagement.
PCMHs have demonstrated that they not only positively impact treatment and
health outcomes, but they also provide significant savings related to hospitalizations and
the management of chronic mental and physical illnesses (Care Management
Technologies, 2016). However, the lack of consistency in PCMH definition and PCMH
component implementation/emphasis, create difficulties in the accurate measurement of
PCMH effectiveness and differentiation between PCMH effectiveness and poor PCMH
execution. The majority of researchers indicated that PCMHs do improve patient
outcomes, particularly for CSHCN, although some PCMH components can have a greater
impact on certain patient outcome measures, even though all components are important.
The purpose of this quantitative research was to examine the impact of PCMHs
on parental beliefs (benefits vs. risks) about ADHD medication and ADHD medication
adherence. This study will address the gap in research related to the efficacy of PCMHs
and their influence on parental ADHD beliefs, as parental beliefs are a strong predictor of
medication adherence (Ferrin & Taylor, 2011). The results of the study will determine
the role of PCMH impact on parental beliefs/attitudes around ADHD medication and
increase parental adherence to ADHD medication for their children. This would increase
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what is known about PCMH’s and their ability to improve treatment outcomes, and thus
advance the role of PCMHs as a viable option to improve medication adherence for this
population. Increased medication adherence for children with ADHD may decrease
academic and social impairment, healthcare utilization, substance use, and risky
behaviors; all of which are detrimental to children’s long-term success. Chapter 3 will
include the study design and rationale, methodology (including population, sampling,
instrumentation, data analysis plan), and threats to validity.
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Chapter 3: Research Method
Introduction
The purpose of this study was to determine if PCMHs have an impact on parental
beliefs related to ADHD medication (benefits vs. risks) and on parental ADHD
medication adherence. In this chapter I detail the research design, population, sample,
instrumentation, data collection, and the plan for statistical analysis.
Research Design and Rationale
The nature of this study was quantitative and utilized a self-report survey
distributed via Qualtrics to determine if PCHMs influenced parental beliefs and
adherence to ADHD medication. There was one subject variable, PCMH, and two
dependent variables, parental beliefs about ADHD medication (benefits vs. risks) and
parental ADHD medication adherence. A multivariate analysis of covariance
(MANCOVA) was used to analyze the data. Potential covariates including age, ethnicity,
gender, education, SES, geography, and parent’s own experience with ADHD medication
were included in the demographic questionnaire. A quantitative survey was the most
effective method to obtain this data because it allowed me to capture data from a large
representative sample of parents who have children with ADHD and also allowed the
participants to remain anonymous. This design choice also allowed me to statistically
test differences between groups and advance what is known about the impact of PCMHs
on parental beliefs and medication adherence.
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Methodology
Population
The target population was parents with children between the ages of 5 and 12 who
had been diagnosed with ADHD and who had been prescribed ADHD medication for at
least three months.
Sampling
A nonprobability self-selected sample of convenience was recruited through
Qualtrics and was drawn from parents who resided within the United States. The
inclusion criteria for survey participation included:
1. Parents must have a child diagnosed with ADHD between the ages of 5 and
12.
2. The child must have been prescribed medication for at least three months.
All who met this inclusion criterion were eligible to participate in the study. This
sampling strategy was chosen because of the large number of participants needed for the
survey and the limited access to this population via other means. A power analysis using
G*Power 3.1 was conducted (Faul, Erdfelder, Buchner, & Lang, 2009) with a suggested
total sample size of 292.
Recruitment, Participation, and Data Collection
Following approval from the Walden Institutional Review Board (IRB), the
survey was made available to potential respondents in the United States with set criteria
through the Qualtrics website (https://www.qualtrics.com). All participants were
required to review the consent form and indicate consent to participate by clicking the
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Next button. Qualtrics is only a medium for data collection, and they do not keep or
utilize information collected from surveys. Survey data was collected from 299
participants within 48 hours of the launch of the survey.
There were four parts to the survey. The first part of the survey gathered the
following demographic information: age, ethnicity, gender, SES, education, geographic
location, and parent’s own experience with taking ADHD medication (Appendix A).
Participants then proceeded to the first set of survey questions (see Table 1), which were
taken from the 2007 NSCH (Centers for Disease Control and Prevention/National Center
for Health Statistics, 2007). These questions were designed to determine whether or not a
person had a PCMH, also referred to as PCMH status, and they have been used by other
investigators to determine PCMH status (Boudreau et al., 2014; Knapp et al., 2013;
Toomey et al., 2011). Participant responses determined the group in which the parents
were placed: PCMH or non-PCMH. The next 10 questions came from the BMQ–
Specific scale and assessed parental beliefs about ADHD medication (benefits vs. risks),
followed by the 8-question MMAS–8, which assessed ADHD medication adherence
(Morisky et al., 2008). Once participants answered all of the questions or if they felt they
did not want to complete the survey, they could exit out of the survey by closing the
page. Participants’ data was anonymous and they were not contacted for any reason
following survey completion.
Instrumentation
Each of the survey instrument authors had been contacted and permission to
utilize them in this research was obtained. The National Survey of Children’s Health is
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in the public domain and therefore the PCMH status questions did not require permission
for use; however, I contacted the U.S. Department of Health and Human Services to
advise of this proposed research.
National Survey of Children’s Health (2007)
The questions in Table 1 were used to determine PCMH status (subject variable):
PCMH or non-PCMH. Survey data from the 2007 NSCH was used to determine
whether the parent utilized a PCMH or a non-PCMH for their child’s healthcare (Toomey
et al., 2007). The NSCH is an accepted method for determining PCMH status and has
been used in several peer-reviewed studies. To meet the criteria for having a PCMH,
participants must answer one of the following to the 12 survey questions (see Table 2):
Yes, Always, Usually, Not a problem, Very Satisfied.
Beliefs About Medicines Questionnaire
This study utilized the BMQ to assess core beliefs that influence parental
adherence to ADHD medication (Horne et al., 1999). The questionnaire is divided into
two sections: the BMQ–Specific and the BMQ–General. The BMQ–Specific evaluates
beliefs related to prescribed medication for a specific disease or illness and is made up of
two scales with a total of 10 questions.
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Table 1
Questions to Determine PCMH Status From the 2007 NSCH
A personal doctor or nurse
1. Do you have one or more persons you think of as your child’s personal doctor or
nurse?
Family-centered care
1. During the past 12 months, how often did child’s doctors and other health care
providers spend enough time with (him/her)?
2. During the past 12 months, how often did child’s doctors and other health care
providers listen carefully to you?
3. When child is seen by doctors or other health care providers, how often are they
sensitive to your family’s values and customs?
4. In the past 12 months, how often did child’s doctors or other health care providers
help you feel like a partner in (his/her) care?
5. When you (or your child) needed an interpreter, how often were you able to get
someone other than a family member to help you speak with (his/her) doctors or other
health care providers?
Problem free referrals*
1. Was getting referrals a big problem, a small problem, or not a problem?
A usual source of care
1. Is there a place that your child USUALLY goes when (he/she) is sick or need advice
about (his/her) health?
2. Is there a place that your child USUALLY goes when (he/she) need routine preventive
care, such as a physical examination or well-child check-up?
Coordinated care
1. During the past 12 months, how often did you get as much help as you wanted with
arranging or coordinating your child’s care?
2. Overall, are you very satisfied, somewhat satisfied, somewhat dissatisfied, or very
dissatisfied with the communication among child’s doctors and other health care
providers?
3. Overall, are you very satisfied, somewhat satisfied, somewhat dissatisfied, or very
dissatisfied with communication among providers and school, special education program
or vocational education program?
*When applicable
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Table 2
PCMH Criteria
Component

Responses

Personal Provider

Yes

Comprehensive Care
•

Usual Source of care

Yes

•

Getting a referral is not a problem

Not a Problem

Family-Centered Care
•

Spent enough time

Usually or Always

•

Listened carefully

Usually or Always

•

Was sensitive to family values and customs

Usually or Always

•

Provided needed information

Usually or Always

•

Partnered in care

Usually or Always

•

Able to get someone other than family member to help

Usually or Always

interpret (if applicable)
Care Coordination
•

Get help coordinating care

Usually or Always

•

Satisfied with communication between providers

Very Satisfied

•

Satisfied with communication between providers,

Very Satisfied

school, and other programs
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The first 5 questions are related to the necessity of ADHD medication to improve health
(benefits), and the second 5 questions are related to the concerns about possible ADHD
medication side effects (risks). The BMQ–Specific was used in this research.
The BMQ–General focuses on a person’s general beliefs about prescribed
medication for treatment. Because this study is interested in understanding specific
parental beliefs about ADHD medication and the benefits and risks of taking it, only the
BMQ–Specific was used in this research. Additionally, the General Harm scale did not
reach statistical significance when correlations between the scale and medication
adherence were evaluated. Horne et al. (1999) also recommended the General Harm
scale be used with caution following results that indicated poor internal consistency in the
asthma, cardiac, and general medical groups.
Participants responded to the BMQ–Specific survey questions via their agreement
with each question, which can range from 1 = strongly disagree to 5 = strongly agree.
Scores from both the necessity and concerns group of questions were summed, with
scores for each scale having a possible range between 5 and 25. Higher positive
difference scores indicate that the participants perceive the medication benefits are
greater than their risks and vice versa for a negative score. This calculation of benefits
versus risks is known as the Necessity-Concerns differential (Horne et al., 1999).
Reliability and Validity of the Beliefs About Medicines Questionnaire
The BMQ scale development included six different illness groups: (a) asthma (n
= 78), (b) diabetes (n = 99), (c) renal dialysis (n = 47), (d) cardiac (n = 120), (e)
psychiatric (n = 89), and (f) general medical (n = 91). A total of 34 statements that were
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representative of frequently espoused beliefs about medication were taken from 16
studies and the investigator-initiated interviews of 34 chronically ill patients. Several
researchers have utilized the BMQ as an effective method for measuring beliefs about
medication. Conn et al. (2005) used the BMQ to assess beliefs about medication and
medication adherence in children with asthma. Brown et al. (2005) also used the BMQ to
evaluate beliefs about antidepressants. Horne et al. (1999) reported the BMQ is suitable
to assess beliefs in all disease states and medication types.
The four measures that were utilized in the development of the BMQ were the
Illness Perception Questionnaire (IPQ; Weinman, Petrie, Moss-Morris, & Horne, 1996),
the Reported Adherence to Medication Scale (Horne et al. 1999), the Sensitive SOMA
Scale (Horne, Faasse, Cooper, Diefenbach, Leventhal, Leventhal, & Petrie, 2013) and
single measures assessing medication-related cognitions. Horne et al. (1999) reported the
psychometric properties of the IPQ were assessed in seven chronically ill groups of
patients, and found the discriminant and predictive reliability, test-retest reliability, and
concurrent reliability were all within acceptable limits.
The Reported Adherence to Medication Scale was developed by Horne et al.
(1999) for the BMQ study to assess medication adherence. It contained four questions:
two scored on a likert scale and two as direct questions. Responses were summed for
each question to provide a total medication adherence score, with better medication
adherence indicated by higher scores. Scores ranged from 0.6 to 0.83 for Cronbach alpha
coefficients on the main sample.
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The Sensitive SOMA Scale assessed participant’s personal sensitivity perceptions
to the possible side effects of medicine. At the time of the BMQ development, this scale
was still under development; however, internal reliability using Cronbach’s alpha in both
groups was reported to be acceptable (general medical = 0.80 and cardiac = 0.78). Single
measures assessing medication-related cognitions were used to evaluate the psychometric
properties of the BMQ.
Criterion validity for the BMQ–Specific-Necessity scale was determined via
correlation with the IPQ scales: Timeline and Identity and correlation with medicationrelated cognition statements. BMQ–Specific-Necessity scores were positively correlated
with the IPQ Timeline scores (Spearman r = 0.49, p < 0.001), which evaluated the likely
length of the illness, and the IPQ Identity scores (Spearman r = 0.24, p < 0.05), which
evaluated the perceived severity of symptoms. A negative relationship between the
medication-related cognition statement, “I can cope without my medicines” (Spearman r
= -0.44, p < 0.001; Horne et al., 1999, p. 18), which assessed medication related
cognitions, and the BMQ-Specific-Necessity scale also supported the criterion validity of
the instrument.
Criterion validity for the BMQ–Specific-Concerns scale was determined in
several ways: (a) the positive correlation between BMQ–Specific-Concerns scale scores
and the following medication-related cognition statements of the asthmatic group, “I
cannot always trust my medicines” (Spearman r = 0.33, p < 0.005; Horne et al., 1999, p.
18) and “I would like to change my present treatment” (Spearman r = 0.37, p < 0.001;
Horne et al., 1999, p. 18); (b) the negative correlation between the BMQ–Specific-
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Concerns scale and the medication-related cognition statement, “I have been given
enough information about my medicines” (Spearman r = -0.45, p < 0.001; Horne et al.,
1999, p. 18) (), which indicated that the person would like more information about their
medication; and (c) the positive relationship between the BMQ–Specific-Concerns scale
and the general medical and cardiac groups scores on the Sensitive Soma Scale
(Spearman r = 0.5, p < 0.001), which indicated a person’s individual sensitivity to the
side effects of the medicines.
The post-hoc Tukey’s HSD tests compared the BMQ mean scores across the
illness groups to determine if the scale could distinguish between patient illness groups.
Discriminant validity of the Specific-Necessity scale was confirmed and indicated the
diabetic group had significantly greater scores than all other groups (M = 21.26, p <
0.01), and the patients in the asthmatic group (M = 19.67, p < 0.01) attained significantly
greater scores than the psychiatric group (M = 17.72, p < 0.01). Significantly greater
Specific-Concerns were also seen in the asthma (M = 15.76, p < 0.01) and psychiatric (M
= 15.60, p < 0.01) groups compared to the others.
Morisky Medication Adherence Scale–8
Lastly, the MMAS–8was used to assess the parent’s adherence to ADHD
medication, which is a validated instrument that has been reported to be reliable for any
medication and/or disease state (Horne et al., 1999). Participants answered eight
questions from the MMAS–8 regarding adherence to ADHD medication (dependent
variable) for their children (Krousel-Wood, Islam, Webber, Morisky, & Munter, 2009;
Morisky et al., 2008; Morisky, & DiMatteo, 2011).
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Morisky Medication Adherence Scale–8 Reliability and Validity
Internal consistency, as measured by Cronbach’s alpha, was 0.83, and was
significantly correlated with the validated MMAS–4 (r = 0.64, p < .05). Morisky et al.
(2008) reported predictive validity of the MMAS–8 was evaluated via correlations with
patient control of their blood pressure, stress, social support, knowledge, and satisfaction
with their visits to the clinic. Morisky et al. reported those with high scores of 8 were
more apt to have controlled blood pressure versus those who had medium or low scores.
Thus, a significant correlation between the MMAS–8 and blood pressure was found (χ2 =
6.6, p < .05). They also found that patient knowledge, stress level, coping, satisfaction,
knowledge, and medication complexity were significant related to medication adherence.
High medication adherence was significantly more likely to occur when patients
expressed greater medical regimen knowledge, satisfaction with their medical care,
experienced positive social support from family members, and had more robust coping
behavior. It is important to note that validation of instruments that capture parent’s
reported medication adherence for his/her child is difficult, largely due to social
desirability and parent concern for potential legal consequences.
Morisky Medication Adherence Scale–8 Scoring
Eight questions are included in the MMAS–8. Questions 1-7 are scored as yes or
no. Question 8 uses a likert scale ranging from “Never” to “All of the time”. A total
score of 8 indicates high parental adherence to ADHD medication, a total score of 6 or 7,
indicates medium adherence to ADHD medication, and a total score of 5 or less indicates
low adherence to ADHD medication. The actual scores were used in this study.
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Data Analysis Plan
This quantitative study evaluated the impact of PCMHs on parental beliefs about
ADHD medication and their ADHD medication adherence. The data was analyzed using
the SPSS 24.0 software package. MANCOVA was utilized to determine if there were
differences in parental beliefs about ADHD medication (benefits vs. risks) and ADHD
medication adherence (dependent variables) between the PCMH (subject variable) and
non-PCMH groups. Data was reviewed for missing values and outliers. If outliers are
detected, they were removed prior to running the MANCOVA. However, the survey was
be set up to require each question to be answered in order to proceed to the next question.
This reduced the potential of skipping any questions. Only completed surveys submitted
through Qualtrics were included in the analysis. The following statistical assumptions
were analyzed and reported for MANCOVA: Multivariate normality, linearity,
homogeneity of variances. The type of test was an F test (One-way MANOVA) and a
between groups subject variable. There was one subject variable, PCMHs, with two
levels, yes or no. There were two dependent variables: 1) parent’s beliefs about ADHD
medications, and 2) adherence to ADHD medication. The results were interpreted using
an effect size of .15, alpha of .05, and power set at .95.
Research Questions
RQ1: Is there a difference between parental beliefs about ADHD medications
(benefits vs. risks), as measured by the BMQ - Specific scale between PCMH and
non-PCMH groups?
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H01: There is no significant difference in parental beliefs about ADHD
medication (benefits vs. risks) between PCMH and non-PCMH groups.
Ha1: There is a significant difference in parental beliefs about ADHD
medication (benefits vs. risks) between PCMH and non-PCMH groups.
RQ2: Is there a difference between parental adherence to ADHD medication, as
measured by the MMAS–8 between PCMH and non-PCMH groups?
H02: There is no significant difference in parental adherence to ADHD
medication between PCMH and non-PCMH groups.
Ha2: There is a significant difference in parental adherence to ADHD
medication between PCMH and non-PCMH groups.
Threats to Validity
The survey was distributed through Qualtrics, and thus, there is no way to ensure
equal participant representation (e.g. ethnicity, age) from across the country. There was
also the possibility that the two groups (PCMH and non-PCMH) were not be equally
represented, or have the same number of participants in each group. Both of these
situations pose a threat to external validity, thus limiting generalization of the results.
Self-report also inherently has some weaknesses. Voils, Hoyle, Thorpe,
Maciejewski, and Yancy (2011) posited instruments that utilize self-report could
demonstrate inadequate reliability. They report these measures are typically 10-20%
below the rates acquired through other methods. Memory recall and the tendency to
overestimate adherence are disadvantages of self-report (Voils et al., 2011).
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Social desirability response bias can also be an issue with self-report and
instrument validity. Van de Mortel (2008) reported some researchers have utilized a
social desirability scale to determine and/or to control for this bias in their research. The
researchers reported that for those who did choose to use a scale, almost 50% of them
reported social desirability did impact study responses. Therefore, these threats were
considered in the data analysis process.
To minimize self-report bias, a statement was written at the beginning of the
MMAS–8 and the BMQ–Specific that encourages participants to be as honest as possible
and references that others have made similar statements. Therefore, participants may
have been more likely to report a true answer. Equal participant representation cannot be
controlled, as participants were a convenience sample distributed via Qualtrics, however
the data was collected anonymously and therefore minimized self-report bias. Threats to
construct validity were minimized through the use of validated instruments (BMQ–
Specific and MMAS–8), which provided appropriate and consistent variable
operationalization, question wording and strong instrument design. Statistical conclusion
validity was minimized through the analysis and report of the following statistical
assumptions for MANOVA: multivariate normality, linearity, and homogeneity of
variances. High statistical power, which was set at .95 also reduced the likelihood of
committing a type I or type II conclusion error.
Ethical Procedures
Following approval of the Walden Institutional Review Board, the survey was
available through Qualtrics. All participants consented to participation via the electronic
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consent form by ticking the “Next” box, and were advised that survey participation was
completely voluntary and anonymous. Participants could withdraw from participation in
the study at anytime without penalty. The electronic survey data was stored securely on a
password protected an encrypted computer and kept for five years. No participant names
or contact information was be collected, only a participant identifier for data management
purposes. Only this researcher and statistician had access to survey data. Participants
were only excluded for the following reasons: a) if the parent does not have a child
within the specified age range, b) the participant’s child has not been diagnosed with
ADHD, or c) the participant’s child has not been prescribed ADHD medication within the
last 3 months. Incomplete surveys were not be included in data analysis, as all questions
had to be answered in order for participants to reach the end of the survey.
Summary
Chapter 3 reviewed the research methods, including the utilization of a
quantitative survey design and the use of Qualtrics to distribute the survey. The sampling
strategy included 294 parents of children with ADHD between the ages of 5 and 12, who
have been prescribed medication for at least three months. The survey included a
questionnaire to determine PCMH status, the MMAS–8 questionnaire to assess parental
ADHD medication adherence, and the BMQ-8 to assess parental ADHD medication
beliefs. Completion of a participant consent form was required to participate in the study.
The data analysis plan utilized a MANCOVA to compare the differences between the
PCMH and non-PCMH groups. Chapter 4 details the data collection procedure, the
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statistical procedures used to analyze the results and to answer the research questions and
hypotheses.
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Chapter 4: Results
The purpose of this study was to determine if PCMHs have an impact on parental
beliefs about ADHD medication (benefits vs. risks) and parental ADHD medication
adherence. Survey data were gathered from 294 parents of children diagnosed with
ADHD. Demographic data and data from the BMQ–Specific, and the MMAS–8 were
collected from parents of children with ADHD. PCMH questions from the 2007 NSCH
were utilized to determine group assignment. In this chapter I review the data collection,
analytic procedures, and statistical results. The following research questions and
hypotheses were examined:
RQ1: Is there a difference in parental beliefs about ADHD medications (benefits
vs. risks), as measured by the BMQ - Specific scale between PCMHs and nonPCMH groups?
H01: There is no significant difference in parental beliefs about ADHD
medication (benefits vs. risks) between PCMH and non-PCMH groups.
Ha1: There is a significant difference in parental beliefs about ADHD
medication (benefits vs. risks) between PCMH and non-PCMH groups.
RQ2: Is there a difference in parental adherence to ADHD medication, as
measured by the MMAS–8, between PCMHs and non- PCMH groups?
H02: There is no significant difference in parental adherence to ADHD
medication between PCMH and non-PCMH groups.
Ha2: There is a significant difference in parental adherence to ADHD
medication between PCMH and non-PCMH groups.
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Data Collection
The original survey host, SurveyMonkey, confirmed on August 4, 2016 that they
would be able to recruit and distribute the survey to the targeted population for this
research via their proprietary database to target participants. However, on April 24,
2017, the week prior to the survey launch, SurveyMonkey advised that they no longer
had access to my targeted population and could not distribute my survey. Thus, the new
survey vendor, Qualtrics, was selected and hosted the survey through an anonymous
survey link on the Qualtrics website (https://www.qualtrics.com). Parents were invited to
participate in the survey via Qualtrics on May 10, 2017. I received 299 responses by
May 11, 2017, following participant consent. The approved Walden University IRB
study number was 05-05-17-0475291.
Description of the Sample
Table 3 displays the frequency counts for the demographic variables in the study.
Most of the parents were White (73.8%) and female (71.1%). Morgan, Staff, Hillemeier,
Farkas, and Maczuga (2013) reported minority children between kindergarten and eighth
grade were 69% less likely to have an ADHD diagnosis than White children. Walsh et al.
(2013) and You, Nam, and Son (2015) also reported up to 88.8% of the time, mothers
were responsible for giving medication at home. These studies support the demographic
breakdown of this study, which is proportional for the population of interest. Incomes
ranged from under $25,000 to over $100,000 with a median of $62,500. Most had
attended some college (34.4%) or had earned a bachelor’s degree or higher (41.2%).
Eighty-seven parents had taken medication for ADHD themselves (29.6%). The sample
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was nationally diverse with at least one survey from 43 different states. The most well
represented states were California (11.9%), Florida (9.5%), New York (7.5%) and Texas
(6.8%). The PCMH criteria met ranged from 1 – 12 (M = 8.26, SD = 2.89). Twentyseven parents, which represented approximately 10% of the sample, met the PCMH
criteria based on their responses to the 2007 NSCH.
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Table 3
Demographic Frequency Counts
________________________________________________________________________
Variable
Category
n
%
________________________________________________________________________
Race
White or Caucasian
Black or African American
Native American or Alaska Native
Asian
Hispanic or Latin American
Other race not described here

217
36
6
4
27
4

73.8
12.2
2.0
1.4
9.2
1.4

Male
Female

85
209

28.9
71.1

49
97
71
45
32

16.7
33.0
24.1
15.3
10.9

Did not complete high school
GED or high school diploma
Some college
Bachelors degree or higher

6
66
101
121

2.0
22.4
34.4
41.2

Yes
No

87
207

29.6
70.4

California
Florida
New York
Texas
All others combined

35
28
22
20
189

11.9
9.5
7.5
6.8
64.3

Gender

Income
$0 - $25,000
$25,001 - $50,000
$50,001 - $75,000
$75,001 - $100,000
More than $100,000
Education

Personally taken
medication for ADHD

State

Note. N = 294.
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Based on the MMAS–8 guidelines (Morisky et al., 2008), most parents scored at a
low level of adherence to ADHD medication (43.2%), 28.6% scored at a medium level of
adherence, and 28.2% scored at a high level of adherence. Children were diagnosed with
ADHD at a mean age of 6.27 years (SD = 1.91), and at the time of the survey had an
average age of 9.04 years (SD = 2.04). They received their first ADHD prescription at an
average age of 6.64 years (SD = 1.92; Table 4).
Table 4
Descriptive Statistics for Selected Child Demographics
________________________________________________________________________
Score
M
SD
Low
High
________________________________________________________________________
Age child diagnosed with ADHD
6.27
1.91
3.00
12.00
Age of child
9.04
2.04
5.00
12.00
Age of first ADHD prescription
6.64
1.92
3.00
12.00
________________________________________________________________________
Note. N = 294
Table 5 provides the psychometric characteristics for the summated scale scores
from the PCMH, benefits, risks, differential, and adherence scales. The Cronbach alpha
coefficients ranged from α = .79 to α = .80. This suggested that all scales had adequate
levels of internal reliability (Cronbach, 1951).
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Table 5
Psychometric Characteristics for Summated Scale Scores
Scale

M

SD

Low

High

Benefits
17.68
3.82
8.00
25.00
Risks
16.84
4.06
7.00
25.00
Differentiala
0.84
4.94
-14.00
15.00
Adherence
5.86
2.15
0.50
8.00
Note. N = 294. a Differential = Benefits scale – Risks Scale

Cronbach’s alpha
.80
.79
n/a
.80

Statistical Assumptions
Initially, 299 people completed the survey. Boxplots identified five univariate
outliers in the benefits scale, and these were removed from the sample (Appendix D). No
outliers were detected in the risks scale. Once the outliers were removed, the differential
score was calculated. This left a final sample of 294, which exceeded the recommended
sample of 292 participants. The following statistical assumptions were analyzed and
reported for MANCOVA: multivariate normality, linearity, and homogeneity of
variances. Skewness and kurtosis were also evaluated (Table 6), and the assumption of
multivariate normality was met. The assumption of linearity was examined using
scatterplots, and this assumption was met (Appendix E). For the MANCOVA model,
Levene’s test for homogeneity of variances found all scales to have equal variances
across groups (benefits [p = .861], risks [p = .301], differential [p = .031], adherence [p =
.971]), and thus, this assumption was also met.
Hypothesis Testing
A MANCOVA was conducted to determine if there were significant differences
between PCMH and non-PCMH groups (independent variable) and parental beliefs about
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ADHD medication (dependent variables: benefits, risks, differential) and adherence to
ADHD medication (dependent variable). An adjustment was made for the following four
covariates: parent’s race, parent’s gender, parent’s income, and parent personally having
taken ADHD medication (Table 6). Following the adjustment, the multivariate analysis
of Pillai’s trace = .032 was significant, F (3, 280) = 3.05, p = .029, partial η2 = .032.
A step down analysis was completed and a significant difference was found
between the PCMH and non-PCMH groups on the differential scale (F [1, 282] = 7.68, p
= .006, η2= .03) when controlling for parental race, gender, income, and personally
having taken ADHD medication. The differential scale is a measure of parental beliefs
about the benefits versus risks of ADHD medication. The mean differential score for the
PCMH group was M = 3.59 and M = 0.56 for the non-PCMH. Both differential scores
were positive, but it was significantly higher for the PCMH group. This indicated there
was a significant difference between groups and demonstrated that PCMH parents scored
higher in their beliefs that the benefits outweighed the risks of ADHD medication.
Therefore, the null hypothesis for the first research question was rejected.
However, there was no statistically significant difference between the PCMH and
non-PCMH groups for the risks scale (F [1, 282] = 2.74, p = .10, η2 = .01) or the benefits
scale (F [1, 282] = 3.55, p = .06, η2 = .01) when controlling for the covariates. The
adherence scale (F [1, 282] = 3.05, p = .08, η2= .01) was not statistically significant and
indicated there was no difference between groups in parental adherence to ADHD
medication and the null hypothesis for the second research question was not rejected
(Table 7).
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Table 6
Covariates for MANCOVA
Covariate

Scale

F

p

η2

Parent’s Race

Risk

8.24

.004

.03

Differential

5.67

.02

.02

Parent’s Gender

Benefits

9.18

.003

.03

Income

Benefits

7.49

.007

.03

Adherence

6.77

.01

.02

Adherence

16.51

.001

.06

Parent Personally
Taken ADHD
Medication

Table 7
Step-Down Analysis for Dependent Variables
________________________________________________________________________
Scale

Met PCMH
Criteria

n

M

SD

Benefits scale
No

267

17.51

3.81

Yes

27

19.33

3.56

Risk scale
No

267

16.96

4.00

Yes

27

15.74

4.65

Differential scale

F

267

0.56

4.80

Yes

27

3.59

5.48

No

267

5.79

2.13

Yes

27

6.53

2.28

η2

3.55

.01

2.74

.01

7.68
No

p

.006

.03

Adherence scale
3.05

.01
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Summary
This study surveyed 294 parents of children diagnosed with ADHD to determine
the impact of PCMHs on (a) parental beliefs about ADHD medication, and (b) parental
adherence to ADHD medication. The results demonstrated that there was a significant
difference between the PCMH and non-PCMH groups for the differential scale, which
assessed parental beliefs about the benefits versus risks of ADHD medication when
controlling for parent’s race, gender, income, and personally having taken ADHD
medication. The PCMH group scored higher in their beliefs that the benefits outweighed
the risks for ADHD medication. However, no statistically significant results were found
for the benefits or risks scales. No statistically significant results were found for the
adherence scale when controlling for the covariates, which indicated there were no
differences in parental adherence to ADHD medication between the groups.
Additionally, parents in the PCMH group had higher incomes and more had personally
taken ADHD mediation compared to the non-PCMH group. In the final chapter, I
compare these findings to the literature draw conclusions and implications, and offer a
series of recommendations.
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Chapter 5: Discussion, Recommendations, and Conclusion
The purpose of this quantitative study was to determine if PCMH's have a
significant impact on parental beliefs about ADHD medication and parental ADHD
medication adherence. ADHD costs billions of dollars for the healthcare and educational
systems and previous attempts to reduce these costs and increase ADHD medication
adherence have not been successful. A MANCOVA was used to analyze the data, with
one variable being PCMH (Yes, No) and two dependent variables, beliefs (benefits, risks,
differential) and adherence. Parent’s race, parent’s gender, parent’s income, and whether
the parent had personally taken ADHD medication were the four covariates included in
the MANCOVA.
The results demonstrated that the PCMH group scored higher in their beliefs that
the benefits outweigh the risks of ADHD medication. However, there were no significant
differences between the PCMH and non-PCMH groups on the individual beliefs scales
(benefits/risks) and the adherence scale. It is important to note that even though the
individual risk scale was not significant, the PCMH components are not designed to
minimize the risks of medication. The PCMH components are designed to help parents
better understand ADHD medication for their children, in spite of the associated
medication risks.
Interpretation of the Findings
Parental Beliefs, Medication Adherence, and Patient-Centered Medical Home Use
This study did not support the literature that indicates positive parental beliefs are
associated with increased medication adherence. Hébert et al. (2013) and Charach and
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Fernandez (2013) found that positive parental beliefs about medication were associated
with the acceptance of pharmacologic treatment options for their children. Ferrin and
Taylor (2011) and Pillow et al. (2014) reported parental beliefs and attitudes around
medication were correlated with parent’s willingness to adhere to medication treatment
for their children. In addition, Toomey et al. (2012) found that parents who believed that
ADHD medication had bad side effects, who were concerned about the long-term effects
of ADHD medication, and who preferred counseling over medication were more likely to
discontinue medication use. Because PCMHs are designed to improve health outcomes
(Adamson, 2011), increase family-based care, enhance medication decision-making
(PCPCC, 2012), and reduce unmet needs through the coordination of care (Boudreau et
al., 2014), it was hypothesized that this study would demonstrate higher parental
adherence to ADHD medication in the PCMH group. However, no significant
differences in adherence were found between the PCMH and non-PCMH groups even
though the PCMH group had higher benefits versus risks belief scores on the differential
scale. These higher belief scores may be attributed to specific PCMH attributes such as
more time provided for medication education and medical provider relationship
development. The results may also be due to the PCMH model in general which
emphasizes the treatment of the patient as a whole, and takes into account culture, social
determinants, and the coordination of both behavioral and physical health needs (De
Vries et al., 2012). However, additional research is required to better determine how the
PCMHs impact the parent’s beliefs.
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Strecher et al. (1986) reported that self-efficacy is associated with a person’s
beliefs in their ability to accomplish particular behaviors. This assertion may have played
a role in why the higher belief scores in the PCMH group did not translate into
significantly higher adherence scores in the PCMH group. Barriers not addressed in this
study such as transportation (Brown & Bussell, 2011), medication costs (Billimek &
August, 2014), and medication side effects (Singh et al., 2010; Toomey et al., 2012) have
been reported to impact medication adherence and are associated with parental selfefficacy. Self-efficacy was not evaluated in this study and further research would be
required to determine what barriers interfere with the conversion of positive parental
beliefs about ADHD medication into increased ADHD medication adherence in the
PCMH group.
Medication Adherence and Persistence
Some of the most noteworthy information gleaned from this data is the length of
medication adherence, which was over two years. The average age that children received
their first prescription in this research was 6.64 years old, and the average age of children
at the time of the study was 9.04 years old. This is contradictory to the literature, which
reports high ADHD medication discontinuation rates within the first 30 to 60 days of
medication initiation. Toomey et al. (2012) reported 42% of children discontinued
medication within 30 days and only 4% continued taking their medication after 6 months.
Raman et al. (2015) reported only 35% of children persisted with medication, even with a
30-day grace period. Avisar and Lavie-Ajayi (2014) found out of a sample of 14, only
five persisted with their medication, and in a study of over 60,000 children, adolescents,
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and adults by Pottegård et al. (2015), fewer than 13% received a second medication refill.
Thus, it is hypothesized that parent report of medication adherence and persistence may
have been inflated as a result of response bias from the desire to provide a socially
desirable answer. The relatively high education level of the sample could also explain
the inflated adherence rates of both groups. Education level is associated with SES and
has been linked to adherence rates (Noble et al., 2015). Although the percentage of
parents with a Bachelor’s degree or higher in the PCMH group (55.6%) was larger than
that of the non-PCMH group (39.3%), these percentages represented the majority of
parents in each group, and thus may explain the unusually high medication adherence rate
in the study overall. A less educated sample may have yielded different results.
Previous Parental Experience with Attention-Deficit/Hyperactivity Disorder
Medication
Hamrin et al. (2010) and Post et al. (2002) reported that parents who had
personally taken ADHD medication are influenced by their experience with treatment,
and this is associated with their acceptance of medication for their children. Hamrin et al.
reported this acceptability of ADHD medication can be attributed to the parent’s ability
to set expectations for their children’s medication use. In this study, parents in the
PCMH group scored higher in their beliefs that the benefits outweighed the risks of
ADHD medication, and 22.2% of them had also personally taken ADHD medication.
However, 30.1% of parents in the non-PCMH group had personally taken ADHD
medication, which does not support the literature that states parents’ previous experience
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with psychotropic medication may positively impact their beliefs about ADHD
medication.
Income, Race, and Gender
SES and race are reported to be contributors to medication beliefs, adherence
(August & Billimek, 2015; Brown & Bussell, 2011; Bussing et al., 2003), and PCMH
attainment (Adams et al., 2013; Knapp et al., 2012; Knapp et al., 2013). Bussing et al.
reported that White parents with higher SES had greater access to larger networks and
healthcare providers from whom to seek advice. According to Brown and Bussell, those
with low SES have decreased access to healthcare. Adams et al. (2013) reported children
with lower income and who were minorities were less likely to have a PCMH. Knapp et
al., (2012) found that White children were almost twice as likely to have a PCMH than
ethnically diverse children. Parents in this study were mostly White in both the PCMH
and non-PCMH groups, although 59.2% of the parents in the PCMH group had incomes
ranging from $50,001 to over $100,000 and 50.7% of the parents had incomes ranging
between $0 and $50,000. The fact that parents in the PCMH group were both White and
had more reported incomes in the higher range is in line with the literature that indicates
PCMH status is associated with SES and ethnicity.
In this study, race was a significant covariate for the differential and risks
scales. The data showed that Whites had a higher differential scale score than nonWhites and non-Whites had a higher risk score. This demonstrated that there were racial
differences related to parental beliefs about ADHD medication and showed non-White
parents rated their beliefs about the risks of ADHD medication higher than. Morgan et
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al. (2013) found that Whites were more likely to take ADHD medication than non-Whites
and may account for why Whites in this study scored higher in their beliefs about the
benefits of ADHD medication.
Income was a significant covariate for the benefits and adherence scales. Parents
who reported their income to be between $75,001 and $100,000 had a higher benefits
scale score, and parents who reported their income to be between $25,001 and $50,000
had a higher adherence scale score. This is counterintuitive because the literature
suggests more positive beliefs related to the benefits of medication are correlated with
greater adherence to medication. It is possible that there were other barriers to adherence
for parents in the higher income group that were not examined in this study.
Gender was a significant covariate for the benefits scale. The benefits scale score
was higher for male parents than for female parents, although male parents represented
fewer than 29% of the total sample. This research did not examine gender-related
differences in beliefs about ADHD medication, and it is not clear why male parents had
higher benefits-related beliefs. However, further exploration of parental gender
differences in beliefs about ADHD medication may be an opportunity for future research.
Theoretical Framework
The study results did not support the theoretical framework. The TPB asserts that
a person’s beliefs and attitudes impact their behavioral intention, and behavioral intention
influences the targeted behavior. In this study, the targeted behavior was parental
adherence to ADHD medication. Although a significant difference in parental beliefs
about ADHD medication was found in the PCMH group, there was no significant
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difference in parental adherence to ADHD medication between groups. Therefore,
positive parental beliefs and attitudes about ADHD medication did not translate into the
performance of the intended behavior, which was adherence to prescribed ADHD
medication. This lack of support of the TPB may be the result of the barriers reported
above such as poor self-efficacy, low SES, and medication side effects, although the
exact reasons are not clear from this research. It is also possible that beliefs must meet a
certain threshold before they are able to change a person’s behavior, which is not a part
of the TPB and would require further study.
The UTB (Jaccard, Dodge, & Dittus, 2002) may be an alternate theory to explain
why the first hypothesis regarding parental beliefs about ADHD medication was
supported and the second hypothesis regarding parental adherence was not. This theory
has been applied to previous research related to medication nonadherence and posits that
although a person’s intentions are influenced to perform a particular behavior, other
factors and barriers can impact the actual occurrence of that behavior. Further research
would be required to determine parental reasons for nonadherence in this population.
Limitations
Medication Adherence Rates and Survey Methodology
A factor that may have played a role in the unusually high parental adherence to
ADHD medication in the study is the use of a survey to determine patient adherence. As
reported in the literature, surveys have inherent flaws, such as self-report bias and social
desirability bias (Voils et al., 2011). In addition, adherence is a difficult behavior to
accurately measure, as people often do not want to report they do not follow medical

99

advice. While there is no gold standard for measuring medication adherence, a more
effective method is through the analysis of pharmacy claims data, which reports
prescription refill rates. This method was utilized by Pottegård et al. (2015) who found
that fewer than 13% of prescriptions were refilled a second time. The use of pharmacy
claims data may have yielded lower parental adherence/persistence rates overall in this
study and revealed differences between the two groups due to more accurate
measurement. Future research should be done with pharmacy claims data to accurately
measure medication adherence.
Patient-Centered Medical Home Group Assignment
For parents to be considered to have a PCMH, their responses to all 12 of PCMHrelated survey questions had to match those on Table 3. If even one of the responses did
not meet the criteria, the parent could not be included in the PCMH group. We know
from the literature that PCMH component execution is inconsistent (Alexander & Bae,
2012; Richmond & Berry, 2012) and is dependent on factors such as insurance
reimbursement for components like assistance with referrals and coordination with other
service providers, and office staff to deliver the component services. Several researchers
contend that as a result of poor provider reimbursement for several of the PCMH
components; such as referral to a specialist, and assistance with medication management
(Antonelli & Antonelli, 2004; Bodenheimer, 2006; Mcallister,et al., 2009), some
providers limit the number of non-reimbursable services they provide (White, 2002) thus
the true measurement of PCMH status is difficult when using the 2007 NSCH.

100

Miller et al. (2015) reported that having all five PCMH components present is
critical to the effectiveness of PCMHs, and if just one of the five components is missing,
there is a reduction in the effectiveness of the PCMH for children with special health care
needs. Richmond and Berry (2012) asserted approximately only 57% of children with
special health care needs received all of the services associated with the five components
of PCMHs, which indicates a significant number of these children do not fully realize the
PCMH benefit. The USDHHS; MCHB (2013) also reported only 43% of children with a
PCMH achieved the full complement of services associated with coordinated and
comprehensive care. The reasons attributed to these disparities in service delivery were
largely attributed to insurance reimbursement for the PCMH components (USDHHS;
MCHB, 2013) as well as poor execution of the components (Alexander & Bae, 2012).
In this study, approximately 68% of parents reported they received assistance with
coordinating care, just over 61% reported their healthcare provider spent enough time
with them, close to 57% indicated they were able to get a non-family member interpret
for them, around 52% reported they were satisfied with communication between
providers, and getting a referral was not a problem, and less than 47% of parents reported
they were satisfied with communication between providers, school, and other programs.
Thus, it may be more realistic to consider a change in some of the PCMH criteria
response requirements to also accept “usually” along with “always” to better reflect the
real-world experiences of patients with a PCMH when utilizing the survey for research
group assignment. In the meantime, Medicaid and other healthcare insurers have moved
closer to providing reimbursement for PCMH components (Arend, Tsang, Quinn, Levine
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& Thomas, 2012), including the time spent to provide assistance with referrals and
coordination with other providers, both of which demonstrated low frequency in
participant reported PCMH criteria in this study.
Disparate Group Sizes
The small number of participants in the PCMH group (n = 27); approximately 9%
of the total sample, may have had an impact on the study outcomes and impact external
validity. The NCQA (2014) reported approximately 10% of primary care practices are
PCMHs and close to 10% of parents surveyed in this study met the PCMH criteria to be
included in the PCMH group. Statistical power may also be impacted by the small
number of participants in the PCMH group and decrease the strength of the results.
Race and Gender
In this study, almost 74% of the parents were White and over 71% of them were
female. This demographic make up can impact the ability to translate the results to the
general population. However, research has shown that the majority of children who are
diagnosed with ADHD between the ages of 5 and 12 are White (Morgan et al., 2013), and
You et al. (2015) reported that most often mothers are responsible for dispensing
medication at home. Non-White parents and males are underrepresented in this study and
limits the generalizability of the results. It is important to conduct further research that
includes a more diverse sample to better understand how PCMHs impact beliefs and
adherence to ADHD medication in all races and genders.
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Recommendations
The first recommendation is the need for a more accurate tool to measure PCMH
status or to adjust the current PCMH criteria to include “usually” along with “always” as
an acceptable response to some of the PCMH criteria (Table 3). This change may more
accurately reflect shortcomings in current PCMH performance, such as staff shortages to
assist with referrals or interpretation services for each patient visit. These shortages are
not necessarily due to PCMH status but can be the result of limited insurance
reimbursement of these services. Further research that relies on confirmed PCMH status,
via accrediting bodies like NCQA and healthcare data, instead of participant responses to
the 2007 NSCH PCMH criteria, may elicit different and/or more accurate participant
group assignment and lead to a more accurate assessment of PCMHs. This method
would provide two groups that are more accurately assigned, provide more accurate
ADHD adherence data, and produce a much larger PCMH group to support more power
and external validity.
Research should also evaluate which PCMH components have the greatest impact
on medication adherence and ways to improve their consistency and execution, and could
prove to bridge the gap between parental beliefs about the benefits of ADHD medication
and enhanced targeted behavior execution (adherence). In this research, 9 of the 12
PCMH criteria questions had a frequency count of less than 75%, which indicated that
parents did not report they received these services all of the time. It may be possible that
an increased report of these services would contribute to a gain in parental adherence to
ADHD medication and is an opportunity for future research.
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Almost 30% of parents in this study reported they had personally taken ADHD
medication. Although this research did not assess if a parent was currently taking
medication for ADHD, Chronis-Tuscano, Wang, Woods, Strickland, and Stein (2017)
reported ADHD symptom severity in the parent primarily involved in childcare could
impact the treatment outcomes of the child. Therefore, it might be important to conduct
this research with more fathers to assess if there are differences in their beliefs and
adherence to ADHD medication.
Implications
This study has positive social change implications as it increases what is known
about PCMHs and how they impact health outcomes. This research revealed that
PCMHs impacted parental beliefs about ADHD medication and found that parents in the
PCMH group scored higher in their beliefs that the benefits outweighed the risks of
ADHD medication. This knowledge may be valuable to healthcare professionals as they
attempt to positively change the health behavior of parents with children with ADHD.
Practitioners can now concentrate on the identification and elimination of barriers that
may interrupt the translation of positive beliefs and attitudes about ADHD medication
into adherence to ADHD medication.
This research also exposed some of the shortcomings in the use of the 2007
NSCH PCMH criteria, which has been used in previous literature (Boudreau et al., 2014;
Knapp et al., 2013; Toomey et al., 2011) to determine PCMH status. In research where
the NSCH is utilized, consideration should be given to PCMH criteria changes that allow
for fluctuations in PCMH component consistency, and/or execution, which currently may
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not be a reflection of PCMH provider status. Lack of provider reimbursement for PCMH
services was identified in the literature (PCPCC, 2016) as a reason for suboptimal PCMH
component delivery. This study supports previous literature in the need for
reimbursement of all PCMH services, which is required to realize the full health benefits
of PCMHs (Miller et al., 2015), and may encourage the transformation of healthcare
delivery as mandated by the Patient Protection and Affordable Care Act.
There are theoretical implications for this study, as this research increases what is
known about the theory of planned behavior (Ajzen, 1991) and challenges how beliefs
influence behavior. The theory asserts that a person’s intention to perform a particular
behavior is the result of the motivational influences on that behavior. It further contends
the stronger one’s intention to participate in a behavior, the greater the likelihood that the
behavior will occur. Therefore, when a person has more positive beliefs, the greater
his/her intention to perform the targeted behavior. This research demonstrated that
parents in the PCMH group scored higher in their beliefs about ADHD medication but
these higher beliefs did not lead to the intended behavior of ADHD medication
adherence. Although significant differences were found in beliefs between groups, it is
possible that there is a belief baseline that must be achieved before behavior is changed.
The theory does not take into account the existence of barriers that may preclude the
execution of the desired behavior, such as financial, access to care, and in particular for
this study, medication side effects and efficacy; which are the two most common reasons
for ADHD medication discontinuance (Toomey et al., 2012).
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Changes to healthcare reimbursement via the Centers for Medicare and Medicaid
and commercial insurers may not only open the door for more widespread delivery of
these services, but it may also provide the opportunity for healthcare providers to offer
more patient-centered and comprehensive care that can benefit the patient, the provider,
and the payor. These benefits include decreased hospitalizations, increased academic
performance, improved peer relationships, and better patient treatment adherence.
Opportunities also exist for further research to examine if PCMHs positively
impact health beliefs in other disease states and patient populations based on the
favorable results found in this study. As healthcare moves from a traditional fee for
service structure to a value-based system of care, providers are required to measure and
report patient outcomes to obtain reimbursement (Porter, Larsson, & Lee, 2016).
Keeping patients healthy is tantamount to successful provider practices and learning how
PCMHs can help achieve this is essential.
Conclusion
This research found that PCMHs positively influenced parental beliefs about
ADHD medication, although it did not find that PCMHs significantly improved parental
adherence to ADHD medication. Further research is needed to determine how PCMHs
can have a positive impact on parental beliefs about ADHD medication and result in
improved parental adherence to ADHD medication. According to the theory of planned
behavior (Ajzen, 1991), changing health beliefs is the first step to changing health
behavior. Although it may be important to understand to what degree beliefs must be
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changed to result in behavior change, and/or how patient barriers to behavior change can
be addressed to support positive behavior execution.
The Patient Protection and Affordable Care Act includes the transformation of
practitioner practices into PCMHs and the identification of several PCMH components
with suboptimal frequency provides a great opportunity for accrediting bodies and policy
makers on which to focus their attention. This targeted approach may change how
healthcare is delivered to this population and may assist PCMHs to improve health
outcomes for children with ADHD.
Methods to increase ADHD medication adherence continue to elude practitioners.
However, additional research that includes a more diverse sample, with certified PCMH
practices, that also measure PCMH component execution, might demonstrate that
PCMHs do increase ADHD medication adherence. Better adherence could decrease the
detrimental factors associated with ADHD, such as poor academic achievement, poor
quality of life, poor family and peer relationships, and increased emergency room visits.
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Appendix A: Demographic Questionnaire

1. Which category below includes your age?
a.
b.
c.
d.
e.

18 -29 years old
30 – 39 years old
40 – 49 years old
50 – 59 years old
60 years old or older

2. Which best describes your race?
a.
b.
c.
d.
e.
f.

White or Caucasian
Black or African American
Native American or Alaska Native
Asian
Hispanic or Latin American
Other race not described here

3. Which best describes your gender?
a. Male
b. Female
4. Which best describes your income?
a.
b.
c.
d.
e.

$0 - $25,000
25,001 - $50,000
$50,001 – 75,000
$75,001 - $100,000
More than $100,000

5. Which best describes your education?
a.
b.
c.
d.

Did not complete high school
GED or high school diploma
Some college
Bachelors degree or higher

6. Have you personally ever taken medication for ADHD?
a. Yes
b. No
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7. Please indicate the state that you live in
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
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•
•
•
•
•
•
•
•
•
•
•
•
•

Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
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Appendix B: Permission to Use to MMAS - 8
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Appendix C: Permission to Use BMQ

Dear Sydney
Thank for your interest in the Beliefs about Medicines Questionnaire (BMQ) in your
research. We ask all potential users to sign up to our standard conditions for use of the
questionnaires.
These conditions are found on the attached CONDTIONS form. They are not designed to
restrict your research with the questionnaire or your rights to publish your findings.
Rather, they are designed to:
-

Preserve the integrity of the questionnaire

Promote uniformity of analysis and presentation (to facilitate comparison of
findings across studies)
BMQ

Ensure that you are using a valid and up-to date version of any disease specific

If you agree to these conditions then please arrange for the Principal Investigator on your
study to sign the form and return it by email. Permission to use the questionnaire is
automatic on receipt on the signed form.
Please let me know if you require further information.
Best wishes
Penny
Penny Weller
BSc MSc Health Psychology
Research Administrator, Centre for Behavioural Medicine
UCL School of Pharmacy
Research department of Practice and Policy
BMA/Tavistock House, Tavistock Square
London WC1H 9JP
Email: p.weller@ucl.ac.uk,
Tel: +44 (0)20 7874 1281
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Appendix D: Box Plots
Risk Scale

Adherence Scale
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Benefits Scale
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Appendix E: Scatterplots
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